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1.1 Gene Therapy  
Gene therapy offers tremendous potential for treatment of inheritated as well as 
acquired diseases. Traditional gene therapy utilizes DNA to correct genetic by 
inserting functional genes into an organism to replace defective ones. If the 
abnormal production of proteins is the cause for disease, gene therapy follows a 
different approach which is posttranscriptional regulation of gene expression. It 
works by silencing specific messenger RNA, for example by using short 
interfering RNA (siRNA), thereby preventing disease-causing proteins from 
being made. For cancer therapy siRNAs offer the potential to eliminate 
neoplastic cells by silencing of genes that are crucial for cell growth and 
viability. 
Gene therapy is likely to become more and more important for disease treat-
ment. The number of clinical trials using gene therapy is steadily increasing. 
Most of the current studies are in phase I stage but some have already reached 
phase II or even III (http://www.wiley.co.uk/genmed/clinical/). However, for effec-
tive treatment, transfer of genetic material needs to reach specific cells of a pa-
tient. The easiest way to do so is the ex vivo approach. Here the relevant target 
cells are isolated from the patient, exposed to the gene of interest in vitro and 
then reinjected into the patient. In most cases the ex vivo approach is not feasi-
ble due to difficult culturing of the cells, reimplantation difficulties or the needed 
cells cannot be solely isolated. Therefore the far more challenging way of in vivo 
gene therapy has to be chosen. Here the cells are directly transfected within the 
patient´s body, which gives rise to several problems which have to be over-
come. First, one has to consider that “naked” DNA or RNA is unstable under in 
vivo conditions due to rapid degradation by serum nucleases (Houk et al. 2001, 
Kawabata et al. 1995). Only in few approaches, like intramuscular injection or 
electroporation, injection of free plasmid leads to effective gene transfection 
(Isaka and Imai 2007, Nishitani et al. 2000). The usage of free siRNA is also 
effective as shown in the treatment of age related macula degeneration in mice 
(Shen et al. 2006) and has already reached phase III clinical trials in humans 
(http://clinicaltrials.gov). However, for this application a stabilized modification of 
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free siRNA has to be used. Therefore, if the nucleic acid (NA) cannot be pro-
tected through chemical modifications within the molecule, carriers or vectors 
are needed to protect nucleic acids from degradation and also to specifically 
target the DNA / nucleotide complex to the cells of interest. These vectors can 
be divided into two major classes: viral and synthetic vectors, wherein synthetic 
vectors include cationic polymers and lipids. 
1.2 Synthetic vectors for gene therapy 
Currently more than two thirds of clinical gene therapy trials use viral vectors 
(http://www.wiley.co.uk/genetherapy/clinical/). Nevertheless, domestication 
might pose inherent problems including immune and toxic reactions as well as 
the potential for viral recombination (for review see: Nair 2008, Yi 2005) 
Chemical modifications for targeting reasons are also difficult.  
As a consequence, a broad range of synthetic vectors have been developed of 
which the use of liposomal formulations and cationic polymers have achieved 
some prominence (Duzgunes et al. 2003, Liu et al. 2003). One main advantage 
of synthetic vectors is that they can be tailored to specific needs, including 
subsequent functionalizations, like targeting or shielding moieties. Nevertheless, 
their transfection efficiency is rather low compared to viral vectors (Brown et al. 
2001). Great efforts have been made during the last years to improve efficiency, 
but still a lot of work has to be done to reach satisfactory levels. 
The group of cationic lipids have become one of the most studied synthetic 
vectors. They are amphiphilic molecules mainly composed of three parts: (i) a 
hydrophobic lipid anchor group; (ii) a linker group, such as an ester, amide or 
carbamate; and (iii) a positively charged head-group, which condenses with 
negatively charged nucleic acids, leading to so called lipoplexes. 
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Fig. 1-1: Schematic representation of the cationic lipid DOTAP (1,2-dioleoyl-3-
trimethylammonium-propane) 
These characteristics cause the cationic lipids to spontaneously assemble into 
nanospheric liposomes when put into aqueous solutions (Mahato 2005). By this, 
nucleic acids (NAs) are compacted and protected against nucleases. Cationic 
lipids are often used in combination with so called helper lipids such as 
dioleoylphosphatidylethanolamine (DOPE) or cholesterol. Both lipids potentially 
promote conversion of the lamellar lipoplex phase into a non-lamellar structure, 
which presumably rationalizes their ability to often improve cationic lipid 
mediated transfection efficiency (Igarashi et al. 2006). But even though 
liposomes are successfully used in clinical gene therapy trials (for review see: 
Fenske and Cullis 2008), concerns were raised regarding immunotoxicity (De 
Smedt et al. 2000, Li et al. 1999).  
In the group of polycations polyethyleneimine (PEI) has achieved some 
prominence and is successfully used in in vitro and in vivo (Godbey et al. 1999, 
Lungwitz et al. 2005) gene therapy. 
Like cationic lipids cationic polymers show extraordinarily good potential to 
condense NAs into nanosized complexes (polyplexes). It is worth mentioning 
that even viruses use “polycations” for NA assembly: NA condensing agents in 
viruses consist of basic and therefore, under physiological conditions, 
cationically charged amino acids. In summary, NA condensation is one of the 
main features needed for efficient gene transfer and can occur with polycations. 
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Even though the immunogenicity of PEI complexes is less distinctive than that 
of liposomal complexes (Kawakami et al. 2006), it is still a major concern. Fur-
thermore a correlation between efficiency and toxicity has been stated in vitro 
and in vivo. To summarize, the ideal vector should combine efficient gene deliv-
ering properties with a decreased toxicity potential. 
1.3 Decreasing immidiate vector toxicity  
One reason for immidiate toxicity (within one hour) observed in vivo is the 
cationic nature of polyplexes (for review see: Lv et al. 2006). The positive 
surface charge on the one hand tends to improve uptake into cells in vitro due 
to higher affinity to negatively charged membrane constituents. On the other 
hand, in vivo applicability of these complexes becomes problematic, since the 
positive surface charge leads to increased non-specific interactions. The charge 
leads to uptake of the complexes by macrophages and rapid removal from the 
blood stream. Furthermore the highly negative zetapotential directs aggregate 
formation with erythrocytes that can cause fatal lung embolism (Ogris et al. 
1999, Plank et al. 1996, Kircheis and Wagner 2000, Chollet 2002). Shielding the 
particle surface with agents such as polyethyleneglycol (PEG) reduces toxicity 
and improves circulation time (Ogris et al. 1999). 
1.4 Decreasing intermediate vector toxicity 
In addition to the immidiate toxic effects, intermediate toxicity of the polycation 
can be observed due to extremely slow, if any, degradation. This will not be 
distinctive until about 24 hours or more after administration. PEI as an example 
tends to accumulate primarily in the liver and causes side effects like 
microvesicular fatty liver (Ogris et al. 2007). The synthesis of biodegradable 
polycations is one possible opportunity to overcome this problem, while 
maintaining high transfection efficiency.  
One proposal is the crosslinking of low molecular weight polycations with bio-
degradable linkers. Ideally these biodegradable polycations will securely guide 
the nucleid acid into the target cell and thereafter get degraded into smaller 
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molecules which can be excreted. One example for this approach that was used 
in the present work are the polycations OEI-HD, lt-OEI-HD1.2 and OEI-HA10, 
wherein OEI stands for oligoethyleneimine, a 600-800 Da low molecular weight 
polyethyleinimine (PEI) fraction used.. The suffixe HD abbreviates the linker 1, 
6-hexanedioldiacrylate that was used to polymerize OEI fractions. In case of 
OEI-HD and lt-OEI-HD1.2 the HD linker reacts with OEI to an ester-based 
polymer (figure 1-2B) and in case of OEI-HD, due to reaction temperature, the 
free amino groups of OEI lead to aminolysis of the esters, generating the 
branched structure displayed in figure 1-2A. The advantage of these polymers 
over the classical PEI lies in their potential of degradability, thus avoiding toxic 
side effects due to accumulation in vivo. 
For OEI-HA10 (figure 1-2C) approximately ten (of approximately 18) nitrogens 
in OEI are reacted with hexylacrylate (HA), producing a hydrophobic polymer, 
which stabilizes formed polyplexes by hydrophobic interactions and potentially 
increases the membrane interaction potential.  
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Fig. 1-2: Structure of OEI-HD (A), lt-OEI-HD1.2 (B) and OEI-HA10 (C) 
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However, even with polycations showing good complexation efficiency and im-
proved in vivo tolerability, intra-cellular delivery of NAs remains a major hurdle. 
1.5 Targeted gene therapy  
Especially for in vivo therapy it is important to target complexes to the 
designated cell of interest to avoid unwanted side effects in normal cells. 
Targeting can be achieved with different strategies:  
(i)  By incorporation of targeting ligands that actively facilitate the uptake 
into specific cells or tissues.  
(ii)  By passive uptake due to special physiological conditions, such as 
irregular fenestration in tumors in connection with tailored complex 
properties.  
(iii)  By the use of cell type specific promoters or enhancers to facilitate gene 
expression in specific cell types.  
Notwithstanding the large amount of research devoted to this subject, active 
targeting is still the largest field of interest. Several ligand-receptor systems 
have been investigated to date. Ligands include antibodies (Jeong et al. 205), 
peptides (Kunath et al. 2003), transferrin (Kircheis et al. 1997), sugars (Zanta et 
al. 1997), mannuronic acid (Weiss et al. 2006), folate  (Chul et al. 2005) and 
growth factors such as EGF (Blessing et al. 2001). In this work, transferrin (Tf) 
was chosen as targeting ligand to provide for efficient intracellular uptake, as 
transferrin receptors are known to be overexpressed by proliferating cells such 
as tumor cells used as in vivo model (Wagner et al. 1991, Wagner et al. 1994). 
Just recently a siRNA nanoparticle delivery system, also containing a transferrin 
receptor targeting agent on the surface, entered Phase I in clinical trials (Press 
release Calando Pharmaceuticals, June 02, 2008, www.insertt.com). 
1.6 Intracellular pathway of complexes 
Spontaneously formed complexes of polycation and NA (where applicable modi-
fied with shielding moieties and or targeting ligands), can be injected into the 
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patients vein and will be delivered to the target tissue by systemic circulation. 
After binding of the vector to the cell surface they are internalized. Once inside 
the cell, release from the endosome is crucial for efficient gene transfer. In the 
case of PEI, a unique endosome-disruptive mechanism, also designated as pro-
ton-sponge-effect (Boussif et al. 1995) is described, making it one of the most 
efficient polycationic gene transfer agents. During processing of endosomes, 
the pH decreases to ~6 in early, ~5 in late endosome and even to pH 4.5 in ly-
sosomes. PEI possesses high buffering capacity leading to increased influx of 
protons, followed by water and chloride ions, thereby inducing osmotic swelling 
and finally by postive charge/membrane interaction to rupture of the endosomal 
membrane. The high transfection efficiency is likely to be linked to this proton 
sponge effect.  
After release into the cytoplasm, siRNA can directly interact with the mRNA, 
representing a clear benefit over DNA which needs to be translocated into the 
nucleus to exert its function. The hypothetical process of polycation/NA complex 
delivery is shown in figure 1-3. Nevertheless, it should be emphasized that 
many steps of this gene delivery process are still under investigation. 
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Fig. 1-3: Hypothetical process of polyplex delivery in vivo. Polycation is modified with 
targeting ligands and shielding moieties. Polycation and NA upon mixing spontaneously 
form polyplexes, which deliver the cargo NA through systemic circulation to the target 
tissue (e.g. tumor). The targeted polyplexes bind to the cell surface via ligand-receptor 
interaction and are internalized (A). Later, complexes are released from the endosome 
(B) and in case of DNA polyplexes DNA is translocated into the nucleus (C), resulting in 
protein expression (D). In case of siRNA its mechanism of action can take place al-
ready in the cytoplasm (E). After incorporation into RISC the antisense strand of the 
siRAN guides the RISC to the homologous mRNA (F), resulting in cleavage of target 
mRNA (G), and gene silencing (H). 
1.7 RNA Interference 
RNA interference (RNAi) is the process by which specific genes can be si-
lenced. It is proposed to be an ancient method of inactivating viral gene expres-
sion (Lindbo et al. 1993). In fact, plants can recover from infection by RNA vi-
ruses via RNA silencing (Ratcliff et al. 1999, Baulcombe 2003). RNAi was first 
reported in plants (Napoli et al. 1990). Studies with the germ line of C.elegans 
(Fire et al. 1998) lead to the recognition that double-stranded (ds) RNA plays a 
pivotal role in this mechanism. However, in the beginning this approach seemed 
unworkable in mammals, because here dsRNA provokes the interferon re-
sponse and causes apoptosis. For normal situations of dsRNA encountering a 
cell (viral infection), this is useful, because it prevents replication and spreading 
of the virus to neighbouring cells. However, for gene therapy this obstacle 
needed to be overcome. By using small synthetic dsRNAs, so called small inter-
fering (si) RNAs (Zamore et al. 2000, Elbashir et al. 2001) with a length of only 
21-25 base pairs this could be achieved. As shown in figure 1-4 siRNAs are a 
natural occuring intermediate of RNA interference. But by using siRNA instead 
of dsRNA Tuschl and colleagues overcame the problem of Toll-like receptor-
detection and immune response, however still obtaining gene silencing. The 
multi-step process of RNA interference is presented in the following figure.  
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Fig. 1- 4: Mechanism of RNAi: After entering the cell, the double-stranded RNA is 
cleaved into shorter fragments of 21 to 25 nucleotides, known as short interfering RNA 
(siRNA), in the cell by an enzyme called Dicer, and the 'sense' strand is degraded. The 
remaining 'antisense' strand is then incorporated into a protein complex called RNA-
induced silencing complex (RISC). The antisense strand of the duplex siRNA guides 
the RISC to the homologous mRNA, where the RISC-associated endoribonuclease 
cleaves the target mRNA resulting in silencing of the target gene. 
1.8 Ran protein 
In this work the potential therapeutic effect of mRNA knockdown in tumor cells 
was studied. As the Ran protein was recently identified from an RNAi based 
screen as possible target in cancer therapy (Morgan-Lappe et al. 2007), we 
have worked with an siRNA directed against the Ran mRNA.The Ran protein is 
a small GTPase and has been implicated in a large number of nuclear proc-
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esses including regulation of nuclear transport and formation and organisation 
of the microtubule network (Sazer and Dasso 2000, Gruss and Vernos 2004).  
 
Fig. 1-5: Ran (ras-related nuclear protein) 
High expression of Ran GTPase is associated with cancer (Abe et al. 2008). 
Because of its pivotal role in nuclear transport (see figure 1-6), our hypothesis 
is that downregulation of the Ran protein results in apoptosis.  
In the cell Ran exists in two nucleotide-bound forms: GDP-bound and GTP-
bound. Transport through the nuclear pore complex is driven by a gradient of 
Ran/GTP, with a high concentration of Ran/GDP in the cytoplasm and a high 
concentration of Ran/GTP in the nucleus. Proteins that should be transported 
into the nucleus contain a nuclear localization signal (NLS) that forms com-
plexes with importin α and importin β in the cytoplasm where Ran is in the GDP-
bound form. Following transport through the nuclear pore complex, Ran/GTP 
binds to importin β, releasing importin α and the protein within the nucleus. 
GTPase-activation then leads to transportation of this complex to the cytoplasm. 
Here hydrolysis of the bound GTP occurs, forming a Ran/GDP complex and 
releasing importin β, thus closing the Ran cycle. 
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Fig. 1-6: Role of Ran protein in nuclear transport 
1.9 Plasmid DNA - design and its impact on gene expression 
The delivered vector in gene therapy can also be bacterial plasmid DNA. How-
ever expression following transfection with systemically delivered plasmid DNA 
(pDNA) complexes is commonly short-lived, due to induction of immune re-
sponse.  
In addition to its therapeutic cargo, such bacterially derived plasmids necessar-
ily contain a backbone with immunstimulatory bacterial CpG motifs. The mam-
malian immune system has been tuned by evolution to recognize the CpG mo-
tifs by activation of Toll-like receptor 9 (TLR-9) as foreign antigens and to mount 
an inflammatory response (Krieg et al. 1995, Hemmi et al. 2000). In case of 
DNA vaccination this is a favoured process, and has made it very attractive for 
immunotherapy against cancer. Nevertheless, for other cases approaches to 
overcome this problem have to be evaluated. To date, there are two different 
ways of minimizing unmethylated CpG sequences. One is the enzymatic methy-
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lation of pDNA and the other is the removal of bacterial sequences, thereby 
generating a minimized DNA vector. 
For comparison studies on the influence of CpG sequences within a plasmid we 
have used two different plasmids (see figure 1-6): pEGFPLuc as a classical 
vector for luciferase expression and pCPGLuc which was cloned by Plasmid-
Factory based on pCpG-mcs and pMOD-LucSh and which shows reduced CpG 
sequences due to removal of bacterial sequences. 
 
Fig. 1-6: Structures of pEGFPLuc and pCPGLuc plasmids that were used for analysis 
of CpG content influence. 
Another problem might appear in the fact that plasmid solutions still contain a 
significant degree of undesired process-related impurities such as bacterial ge-
nomic DNA. Through purification by high performance liquid chromatography 
(HPLC) this amount can be reduced from ~ 10 to 15 % down to ~ 1 %. 
In this work we have analyzed the influence of CpG depletion and purification of 
plasmids concurrently to further enhance transgene expression both in vitro and 
in vivo. 
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1.10 Specific aims of this work 
In this dissertation, systemic delivery of NAs, alone and complexed with polyca-
tionic delivery systems, was analysed. The analysis was focused on tolerability 
and efficiency of the treatment.  
The in vivo administration is so far hampered by the lack of stable delivery sys-
tems that are able to protect their NA cargo in the blood stream and savely lead 
it to the desired target cells. However, two novel polycationic vectors that had 
been established in our lab, led to promising results for siRNA delivery in vitro. 
In the current work we have therefore tried to optimize siRNA / polycationic 
complexes for in vivo administration. Furthermore, we have used the therapeu-
tically relevant RAN siRNA to influence the growth of subcutaneous Neuro2A 
tumors in an in vivo model. 
Another aim was to evaluate different biodegradable polymers, that had been 
established in our lab, for their efficiency and safety in in vivo application. Poly-
mers were compared with L-PEI as a gold standard regarding efficiency. How-
ever, L-PEI can not be degraded within the body and can thereby lead to a long-
term toxicity. In contrast, we wanted to show that our biodegradable polymers 
can reach efficiency levels as high as L-PEI, yet compared with a much better 
tolerability and the possibility of repeated application. 
Furthermore we were interested in clarifying the impact of the NA on efficiency 
and toxicity of the treatment. In this case we have compared plasmid DNA con-
taining bacterially derived CpG motifs, with plasmid DNA that was exempt from 
CpG sequences.  
But because plasmids are generated in bacteria and the plasmid purification 
step leaves behind a certain amount of bacterial genomic DNA, we also wanted 
to clarify the impact of this (CpG containing) impurities. One approach was to 
compare the effect of the plasmids alone. For this analysis we had chosen the 
possibility of hydrodynamic tail vein injection of plasmid solutions in mice. An-
other approach was to compare the plasmids when they were complexed to L-
PEI as a gold standard for polyplex delivery.                   
 2 Materials and Methods
2 Materials and Methods 21 
 
2.1 Reagents and chemicals 
The plasmid pEGFPLuc (Clontech Laboratories, Heidelberg, Germany) containing a 
CMV promoter driven fusion of the genes encoding for enhanced green fluorescent 
protein and luciferase was used for generation of stably transfected cells. Lipofec-
tamine 2000 (LF2000) was obtained from Invitrogen (Karlsruhe, Germany). Linear 
PEI  with an average molecular weight of 22 kDa (PEI22) was synthesized by acid-
catalysed deprotection of poly(2-ethyl-2-oxazoline) (50 kDa, Aldrich) in analogous 
form as described (Brissault et al. 2003) and is also commercially available from 
Polyplus (Strasbourg, France). Branched PEI with an average molecular weight of 25 
kDa (PEI25) was obtained from Sigma-Aldrich (Munich, Germany). PEIs were used 
as a 10 mg/ml stock solution neutralized with HCl. Transferrin was obtained from Bio-
test (Dreieich, Germany). Transferrin conjugated OEI-HD (Tf-PEG-OEI) was synthe-
sized and purified in analogous manner as Tf-PEG-PEI conjugate described in 
(Kursa et al 2003). Oligoethylenimine derivative OEI-HD (Kloeckner et al. 2006-1, 
Kloeckner et al. 2006-2, Kloeckner et al. 2006-3) is based on OEI 800 Da crosslinked 
by ß-aminoproprionamide linkages and was synthesized by Abbott GmbH ( Chicago, 
IL, USA). The optimized procedure as described in (Tarcha et al. 2007) generates 
OEI-HD polymers with a typical molecular weight of 25-30 kDa. OEI-HA10 was syn-
thesised in our work group (Arkadi Zintchenko, unpublished data), lt-OEI-HD1.2 was 
synthesized as described in (Kloeckner et al. 2006-3),using a polymer to linker ratio 
of 1:1.2.  
All other chemicals were purchased from Sigma-Aldrich (Munich, Germany). Cell cul-
ture media, antibiotics and fetal calf serum (FCS) were purchased from Invitrogen 
(Karlsruhe, Germany). siRNA duplexes were purchased from Dharmacon (Lafayette, 
CO, USA); LucsiRNA: GL3 luciferase specific duplex: 5'-
CUUACGCUGAGUACUUCGAUU-3', non-specific control siRNA siCONTROL: 5'-
UAGCGACUAAACACAUCAAUU-3' und RAN specific therapeutic siRNA RANsiRNA:  
5’-AGAAGAAUCUUCAGUACUAUU-3’ were used. RNA stabilization solution 
RNAlater was purchased from Qiagen (Hilden, Germany). RT-PCR primers were 
purchased from Eurofins MWG Operon (Ebersberg, Germany) and Roche Diagnos-
tics (Mannheim, Germany) and are further described in chapter 2.21. All other re-
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agents for RT-PCR were also obtained from Roche Diagnostics. D-Luciferin, sodium 
salt is available from Promega (Mannheim, Germany). 
2.2 Plasmid design 
Three different types of DNA were used in this work. pCMVLuc carrying the firefly 
luciferase coding region under the promoter control of cytomegalovirus (CMV)  was 
provided by Plasmid Factory (Bielefeld, Germany).  
pCpGLuc and pEGFPLuc were amplified by Plasmid Factory and provided in two 
different purification grades. (i) Research grade (RG, containing up to 15 % genomic 
DNA) (ii) Covalently closed circular grade (ccc, containing max. 1 % genomic DNA). 
The amount of genomic DNA in the ccc versions is ~ 1 % compared to ~10-15 % in 
RG plasmids.  
EGFPLuc plasmid was in addition amplified in our group with a competent E. coli 
strain JM 109 (Promega) and purified with the EndoFree Plasmid Kit according to a 
protocol from Qiagen (Hilden, Germany). 
2.3  Formation of transfection complexes 
Formulations for siRNA and pDNA delivery, respectively were prepared as follows: 
First, different concentrations of NA and polymer were diluted at various polymer/NA 
ratios (w/w: weight/weight) in separate tubes in equivalent HBG amounts (HEPES 
buffered glucose solution; 20 mM HEPES, 5% glucose, pH 7.4). Then, the HBG solu-
tion of the polymer was added to the NA, mixed and incubated for 30 to 40 min at 
room temperature to form polymer/NA complexes. Transferrin-conjugated poly-
mer/NA-formulations were prepared as described above with the exception that the 
polymer was partially replaced with corresponding weight percentages (5, 10, 25, 35, 
50 %) of Tf-conjugated polymer, where the weight percentages refer to the polymer 
component of the Tf conjugate. Replacing for example 5, 10, or 50 % of the OEI-HD 
with Tf-PEG-conjugated OEI results in transferrin: OEI weight/weight ratios of 0.21/1, 
0.41/1 or 2.1/1, respectively, with 17 %, 29 %, or 68 % of the weight of the blended 
carrier being composed of transferrin protein.  
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2.4 Measurement of particle size and zeta-potential 
Particle size of various polymer/NA formulations were measured by dynamic laser-
light scattering using a Malvern Zetasizer Nano ZS (Malvern Instruments, Worcester-
shire, UK) equipped with a 4 mW He–Ne laser at a wavelength of 633 nm at 25 °C. 
Scattered light was detected at a 173° backward scattering angle. The viscosity and 
refractive index of water at 25 °C was used for data analysis. For particle sizing com-
plexes were prepared as for gene transfer and diluted in HBG to give a final NA con-
centration as used for transfection. For estimation of the zeta-potential, transfection 
complexes were first prepared in HBG, then 1 mM NaCl was added to achieve ap-
propriate volume for measurement and the zeta potential was determined. Dispersion 
Technology Software 5.00 (Malvern Instruments, Herrenberg, Germany) was used for 
data analysis. All data represent the mean of three independent measurements. 
2.5 Cell culture experiments 
For pDNA delivery experiments, mouse neuroblastoma cells Neuro2A (ATCC; CCL-
131) were used. The cells were grown in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10 % serum and 4 mM stable glutamine. All cells were 
seeded 24 hours prior to pDNA delivery using 5,000 cells per well in 96-well plates 
for transfection and cytotoxicity experiments. 
2.6 Transfection in vitro 
For standard in vitro transfection cells were seeded in 96-well plates using 5,000 cells 
per well 24 hours prior to transfection. Experiments were performed in 100 µL growth 
medium containing 10 % fetal bovine serum (FCS). Transfection complexes with indi-
cated amounts of pDNA were then added to each well. Complex containing medium 
was removed after 4 hours, 100 µl of fresh medium was added and cells were ana-
lyzed for cytotoxicity of complexes or luciferase reporter gene expression, respec-
tively after 24 hours. 
2.7 Cytotoxicity assay 
The cells were grown in 96-well plates and treated with different amounts of pDNA 
complexes as described in chapter 2.6. Cell viability was determined 1 day following 
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transfection by addition 5 µg of MTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxyanilide] (Sigma) to each well. Cells were incubated at 37°C/5% 
CO2 for up to two hours. Medium was removed and samples were frozen at – 80 °C 
for at least 2 hours. 100 μl of dimethyl sulfoxide (DMSO) was added and samples 
were further incubated at 37 °C/5% CO2 for 30 min under constant shaking. Absorb-
ance was measured spectrophotometrically at 450 nm.  
The relative cell viability (%) was related to control wells containing cell culture me-
dium without polyplex and was calculated by: absorption test x 100 % / absorption 
control. 
2.8 Luciferase reporter gene expression 
Twenty four hours following pDNA delivery (see chapter 2.6), medium was removed, 
cells were washed with phosphate-buffered saline (PBS; pH 7.4) and lysed with 50 
µL of lysis buffer (25 mM Tris, pH 7.8, 2 mM EDTA, 2 mM DTT, 10 % glycerol, 1 % 
Triton X-100). Luciferase activity was measured using a Lumat LB9507 instrument 
(Berthold, Bad Wildbad, Germany). Luciferase light units were recorded from an ali-
quot of the cell lysate with 10 s integration time after automatic injection of freshly 
prepared luciferin (Luciferase Assay System, Promega, Mannheim, Germany). Lu-
ciferase activity was measured in triplicate and the relative light units (RLU) were de-
termined.  
2.9 Hemolysis of erythrocytes 
A/J mouse erythrocytes were isolated from fresh citrate treated blood and washed in 
phosphate-buffered saline (PBS) by four centrifugation cycles at 800 g each for 10 
min. at 4° C. The erythrocyte pellet was diluted with PBS  to give 6000 erythrocytes 
per ml . Polymer was diluted in HBG, containing 10 % FCS to reach final concentra-
tions of 0.01 to 0.1 mg/ml. Erythrocyte suspension was added to each well and plates 
were incubated at 37 °C for 30 min under constant shaking. After centrifugation at 
300 g for 10 min, 80 μl supernatant was analyzed for hemoglobin release at 405 nm 
using a microplate plate reader (Spectrafluor Plus, Tecan Austria GmbH, Grödig, Aus-
tria). Erythrocyte suspensions treated with HBG / FCS buffer (10 % v/v FCS) only 
and 1 % Triton-X-100 served as negative and positive controls, respectively. 
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2.10 Polymer induced erythrocyte aggregation 
To study polymer induced aggregation of erythrocytes, erythrocyte pellets were used 
(see chapter 2.9). Pellets were resuspended in 1 ml HBS and transferred to a 24 well 
plate. Pictures were taken using an Axiovert 200 microscope (Carl Zeiss, Jena, Ger-
many) equipped with an Infinity 2 CCD camera (Lumenera Corporation, Ottawa, On-
tario, Canada). Aggregation was visualized at a 51-fold magnification. 
2.11 Ethidium bromide exclusion assay 
DNA condensation of OEI-HD and lt-OEI-HD1.2 was measured by quenching of 
ethidium bromide fluorescence. Ethidium bromide was diluted either in HEPES-
buffered saline (HBS, 20 mM HEPES, 150 mM NaCl, pH 7.4) or HEPES-buffered 
glucose (HBG, 5 % (w/w) glucose, 20 mM HEPES, pH 7.4) to give a final concentra-
tion of 0.4 µg/ml. Two ml of ethidium bromide solution were mixed with 20 µg of 
pDNA. After 3 minutes incubation time, polycation was added and fluorescence in-
tensity was measured over time. The fluorescence was measured on a Cary Eclipse 
fluorescence spectrophotometer (Varian Deutschland GmbH, Darmstadt, Germany) 
at λex = 510 nm and λem = 590 nm. Results are given as relative fluorescence and 
the value of 100% is attributed to the fluorescence of free DNA with ethidium bromide 
(rel. F = Fsample/FDNA solution). 
2.12 Polyplex stability in heparin 
Increasing amounts of heparin in 10 μL pure water were added to 100 μL polyplex 
solution, yielding heparin concentrations of 0.05 to 2.5 international units (IU) per μg 
plasmid, and incubated for 30 minutes at room temperature. 10 μL of this mixture 
was applied to a 1% agarose gel containing 0.5 ng/ml of ethidium bromide. Gels were 
run for 70 minutes at 70 V, prior to the scanning with a gel documentation system 
(Raytest Isotopenmeßgeräte GmbH, Straubenhardt, Germany). Images were proc-
essed with Image J (National Institute of Health, Bethesda, MD, USA). 
2.13 Animals 
A/J mice (8-12 weeks, 20-23 g) were purchased from Harlan Winkelmann (Bicester, 
UK) and BALB/c mice (8-12 weeks, 20-23g) were purchased from Janvier (Le Gen-
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est-St-Isle, France). Mice were kept under specific pathogen free conditions with a 12 
h day/night cycle. Standard breeding chow and water were provided ad libitum. All 
animal procedures were approved and controlled by the local ethics committee and 
carried out according to the guidelines of the German law of protection of animal life. 
2.13.1 In vivo applications for RNAi experiments 
A/J mice were injected subcutaneously with 1x106 Neuro2A cells. After 1 week, when 
tumors had reached approximately 3 mm in size, polymer/siRNA formulations were 
applied using intravenous injection of complexes via the tail vein (2.5 mg siRNA / kg). 
OEI-HD/Tf-PEG-OEI/siRNA polyplexes were formed at the OEI-HD/siRNA w/w ratio 
0.6/1 containing 10 % targeting Tf conjugate, and were applied at concentrations of 
175 µg/ml siRNA, 94.5 µg/ml OEI-HD and 10.5 µg/ml OEI conjugated to Tf-PEG in 
sterile HBG. The blended carrier in this case contained 43 µg/ml transferrin, i.e. 29 % 
transferrin by weight of total polymer. Mice were separated into three groups (n = 5 
per group): (i) animals treated with therapeutic RAN siRNA, (ii) animals treated with 
unspecific mismatched Mut siRNA and (iii) non-treated animals. Injections were ap-
plied 3 times, every three days. Tumor size was measured over time every day dur-
ing the whole experiment using a digital caliper. The size is given in length x width x 
hight (mm3). Two days following the last administration, animals were sacrificed and 
blood was collected. For histological analysis one half of each organ explanted (liver, 
lung, spleen, tumor) was fixed for 24 h in formalin solution (4 % paraformaldehyde in 
PBS). Afterwards organs were rinsed with water before tissue was dehydrated under 
vacuum in 70 %, 80 % and 100 % (v/v) ethanol and three times in 100 % xylol. Next, 
organs were placed in paraffin three times for three hours under vacuum follwed by 
embedded in paraffin. The remaining organ parts were frozen in liquid nitrogen and 
stored at -80 °C until further analyzed by Western Blot and qPCR. 
2.13.2 In vivo applications of plasmid DNA 
2.13.2.1 Low pressure tail vein injections 
BALB/c mice were treated intravenously with 200 µl of complexes containing 50 µg 
plasmid per 20 g mouse. Complexes were formed with L-PEI, as described above, in 
the L-PEI nitrogen / DNA phosphate (N/P) ratios 5/1, 6/1 and 9/1. Polyplexes with the 
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following plamids were analyzed (n = 3-4): (i) pCpGLuc RG, (ii) pCpGLuc ccc, (iii) 
pEGFPLuc RG and (iv) pEGFPLuc ccc. 
After intraperitoneal luciferin injection, transfection efficiency was measured over time 
by a CCD camera (see chapter 2.12) 6 h, 24 h and 72 h after transfection. One sup-
plementary group of animals was sacrificed 24 h post transfection, blood was col-
lected for cytokine expression detection and organs were explanted for additional 
luciferase expression analysis by tube luminometer.  
2.13.2.2 High pressure pDNA tail vein injections 
Eight week old female BALB/c mice were placed into a restraining device and anes-
thetized with isoflurane, which was administered by inhalation (2.0% (v/v) isoflurane 
in oxygen at a flow of 1 liter/min). Intravenous injections were performed by injecting 
a plasmid solution (12.5 µg /ml in isotonic sodiumchloride solution (B Braun Meslun-
gen AG, Melsungen, Germany)) in a volume corresponding to 12 % of the total body 
weight within approx. 5 seconds (this corresponds to 2.4 ml in case of 20 g body 
weight) using a 30 gauge needle (0.3 x 12 mm) (Sterican, B Braun Melsungen 
AG).Transfection efficiency was measured over time 10 minutes after intraperitoneal 
luciferin injection by a CCD camera (see chapter 2.12) for a period of several weeks. 
2.13.3  In vivo applications for polymer comparison 
For in vivo experiments A/J mice received 1 x 106 Neuro2a cells in 100 µl PBS sub-
cutaneously. After tumors reached sizes of about 7 mm in diameter, pDNA complexes 
containing 50 μg of EGFPLuc plasmid, diluted in sterile HBG, were injected into the 
tail vein. Injection volume was 10ml/kg bodyweight. The following polymers were ap-
plied as complexes: (i) L-PEI, (ii) OEI-HD1 and (iii) lt-OEI-HD1.2. 
Forty-eight hours after application animals were sacrificed and blood was collected 
for liver enzyme detection. Organs were cut into half and luciferase activity was 
quantified in tumor and organs as described in chapter 2.11.3 with one half. The re-
maining organ parts were kept for histopathological analysis. 
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2.14 In vivo Imaging 
For luciferase expression experiments mice were anesthetized before imaging at 
various time points using isoflurane (2.0% (v/v) isoflurane in 1 liter/min oxygen flow). 
D-Luciferin (30 mg/ml, pH 7) was injected intraperitoneally into the mice at a dose of 
150 mg/kg. A greyscale reference image of the mice position was taken prior to bio-
luminescent image. At 10 min post-luciferin injection bioluminescent signals were as-
sessed at an integration time of 1 to 5 min using an in vivo imaging system that util-
izes a cooled-charge-coupled device (CCD) camera (Ivis 100, Caliper Life Sciences, 
Hopkinton, MA, USA). All images were analysed using the Living Image 2.50 soft-
ware.  
2.15 Luciferase gene expression detection in situ 
For additional luciferase expression anaylsis, explanted organs were homogenized in 
cell lysis buffer (Promega, Mannheim, Germany) with an Ultra-Turrax T8, dispersing 
tool S8N-5 G (IKA Werke, Staufen, Germany), and centrifuged for 10 min at 4000 g 
and 4 °C. The supernatant was analyzed for relative light units of luciferase with 30 s 
integration time after automatic injection of freshly prepared luciferin using the Lumat 
LB9507 instrument (Berthold, Bad Wildbad, Germany).  
2.16 Blood analysis 
Blood was collected by heart puncture immediately after sacrification using 
heparinized syringes. Counts of white blood cells, red blood cells and platelets were 
determined immediately following sample collection using a Sysmex XE-2100 whole 
blood analyser (Sysmex, Norderstedt, Germany). For the determination of various 
blood enzymes samples were allowed to clot at 37 °C for 4 h, overnight at 4 °C, then 
centrifuged at 3000 g for 20 min at 4 °C and the supernatants were collected for se-
rum analysis. Alkaline and aspartate aminotransaminases (ALT, AST) as well as alka-
line phosphatase (AP) were determined using a kinetic UV test from Olympus (Olym-
pus Life and Material Science, Hamburg, Germany). Glutamate Dehydrogenase in 
plasma was analyzed using a kinetic UV test from Hitado (Hitado Diagnostic Sys-
tems, Möhnesee Delecke, Germany). 
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2.17 Cytokine antibody array 
Mouse Cytokine antibody array 1.1 (Ray Biotech Inc., Norcross, GA, USA) consisted 
of 40 different cytokine and chemokine antibodies spotted in duplicate onto a mem-
brane. Cytokine membranes were processed according to the manufacturer's instruc-
tions. In brief, membranes were blocked with 10 % bovine serum albumin in Tris-
buffered saline for 30 minutes at room temperature. Membranes were then incubated 
with mouse plasma samples (10-fold dilution with blocking buffer) for 2 hours at room 
temperature. After extensive wash with Tris buffered saline (TBS; 0.5M Tris Base, 9 
% NaCl, pH 7.6) / 0.1 % Tween 20 and TBS alone to remove unbound cytokines, 
membranes were incubated with biotin-conjugated anti-cytokine antibodies. Mem-
branes were again washed and then incubated with horseradish-peroxidase-
conjugated streptavidin (2.5 pg/ml) for 1 hour at room temperature. Unbound material 
was washed out with TBS / 0.1 % Tween 20 and TBS. Spots were visualized using a 
peroxidase substrate detection buffer. Membranes were exposed to Kodak X-Omat 
radiographic film for 1 minute for image. Membranes were scanned and spots were 
quantified using NIH image analysis software (Image J). Membranes were compared 
by normalizing the positive control readings. 
2.18 Histopathological examination 
For histopathological analysis organs were dehydrated and embedded in paraffin 
using a Shandon Excelsior (Thermo Fisher, Schwerte, Germany). After paraffin effu-
sion organs were cut into 5 µm thick sections and stained with hematoxylin and eosin 
for histopathological examination. Pictures were taken using an Axiovert 200 micro-
scope (Carl Zeiss, Jena, Germany), equipped with an Infinity 2 CCD camera (Lu-
menera Corporations, Ottawa, Canada). Histology was visualized at a 51-fold magni-
fication. 
2.19 TUNEL staining of tissue sections 
For determination of apoptosis the ApopTag® Fluorescein kit from Qbiogene (Heidel-
berg, Germany) was used according to the manufacturers’ protocol. Briefly, organs 
were embedded in paraffin as described in 2.15 and cut into 5 µm thick sections. Af-
ter that sections were deparaffinized and treated with 5 mg/mL proteinase K for 15 
min at room temperature and inactivated endogenous peroxidase with 3 % H2O2. 
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Sections were then incubated with TdT enzyme and biotin-labeled and -unlabeled 
deoxynucleotides at room temperature for 30 min in the dark. Nuclei were counter-
stained with 4',6-Diamidino-2-phenylindol (DAPI). Cell imaging was performed using 
a confocal laser scanning microscope (LSM 510 Meta, Carl Zeiss, Jena, Germany) 
equipped with an argon and two helium / neon lasers delivering light at 488, 543 and 
633 nm, respectively. Light was collected through a 63 x oil immersion objective 
(Zeiss). Simultaneous scans for fluorescein and DAPI were carried out with an excita-
tion wavelength of 488 nm (emission 505 nm long-pass) and 351 nm (385-470 nm 
and-pass) respectively. Digital image recording and image analysis were performed 
with the LSM 5 software (Zeiss).  
2.20 Western Blot Analysis 
For in vivo experiments 50 µg protein per lane was separated by SDS-PAGE under 
reducing conditions. Proteins were then transferred on a PVDF membrane and 
blocked with 5 % skimmed milk for one hour at room temperature. Immunostaining 
was performed using primary Ran antibody (Cell Signaling/Sigma RBI, Taufkirchen, 
Germany;  1:500) over night at 4°C according to manufacturer’s protocol and peroxi-
dase labelled anti-rabbit-IgG (Cell Signaling; 1:2000) as the secondary antibody for 
two hours. Ran protein was visualized using ECL western blotting detection system 
(Upstate, Temecula, CA, USA). In addition, for the internal correlation of protein ex-
pression of each sample, detection of the housekeeping protein for α-tubulin was per-
formed using mouse primary antibody (Cell Signaling, 1:5000) for one hour following 
incubation with anti-mouse HRP-secondary antibody (Cell Signaling, 1:5000) for an-
other hour. For quantification, first Ran protein expression of each sample was nor-
malized for the expression of the housekeeping protein for α-tubulin and quantifica-
tion was performed using ImageJ (National Institute of Health, Bethesda, MD, USA). 
2.21 RNA isolation 
For evaluation of siRNA experiments RNA from mouse tumors was isolated after sta-
bilising tissue over night at 4°C with RNAlater (Qiagen). Tumors were then snap fro-
zen with liquid nitrogen and crushed in a plastic bag with a hammer. The tumor pow-
der was further processed for RNA isolation by using the NucleoSpin RNA II Kit 
(Macherey Nagel) as described by the manufacturer. Briefly, tissue was denaturated 
by adding of ß-mercaptoethanol. Viscosity was reduced by filtration of the lysate 
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through filter units. 70 % ethanol (v/v) was used for precipitation of nucleic acids and 
precipitate was loaded on silica filters. The matrix was desalted and then DNA was 
removed by treatment with DNAse. Silica matrix was then washed and RNA diluted 
with RNAse free water.   
2.22 Reverse transcription of RNA to cDNA 
RNA was reverse transcribed by High Capacity RNA-to-cDNA Master Mix (Applied 
Biosystem, Darmstadt, Germany) as described by the manufacturer. Briefly, 100 ng 
of extracted RNA was added to 4 µl of a cDNA synthesis reaction mixture containing 
random hexamers (total volume of 20 µl). Samples were then incubated at 37°C for 
60 min, followed by 5 min at 95°C. 
2.23 Real-time polymerase chain reaction (RT-PCR) 
For determination of the most stable housekeeping gene, preliminary RT-PCR was 
performed using the four commonly used housekeepers ATP synthase, ß-subunit 
(ATP5B), Cytochrom C1 (CYC1), ß-Actin (ACTB), glyceraldehydes-3-phosphate de-
hydrogenase (GAPDH). All primers were designed using the ProbeFinder qPCR as-
say design software, which is freely accessible at www.universalprobelibrary.com, 
and constructed as follows: 
Ran:  
forward  5´ACCCGCTCGTCTTCCATAC 
reverse  5´ATAATGGCACACTGGGCTTG, 121 bp 
ATP5B:  
forward  5´GGCACAATGCAGGAAAGG  
reverse  5´TCAGCAGGCACATAGATAGCC, 77 bp 
CYC1:  
forward  5´ACCTGGTGGGAGTGTGCTAC 
reverse  5´CATCATCATTAGGGCCATCC, 84 bp 
ACTB:  
forward  5´CTAAGGCCAACCGTGAAAAG 
reverse  5´ACCAGAGGCATACAGGGACA, 104 bp 
2 Materials and Methods 32 
 
GAPDH:  
forward  5´AGCTTGTCATCAACGGGAAG 
reverse  5´TTTGATGTTAGTGGGGTCTCG, 62 bp 
RT-PCR amplification mixture (20 µl) contained template cDNA (1:500 dilution), 200 
nM forward and reverse primer, 100nM Universal Probe Library probe and the Light 
Cycler 480 Probes Master. Reactions were run on a Light Cycler 480 (Roche Diag-
nostics GmbH, Mannheim, Germany). RT-PCRs were performed with a pre-
denaturing step of 95°C for 10 minutes and 45 cycles of 95°C (10 seconds), 60°C (30 
seconds), and 72°C (10 seconds) followed by a cooling step at 40°C for 1 minute. 
The crossing-point (Cp) value from each signal was calculated based on the second 
derivative maximum method performed by the LightCycler 480 quantification software 
(version 3; Roche Diagnostics GmbH) followed by geNorm analysis (geNorm VBA 
applet: http://medgen.ugent.be/genorm/) was used for detection of the most stable 
gene. A set of serially diluted cDNAs was used to construct a 4 data-point standard 
curve for every PCR system. 
After detection of the most stable housekeeping gene, a multiplex assay for simulta-
neous detection of target and reference gene was used. For ACTB new primers were 
designed using the ProbeFinder qPCR assay design software: 
forward:  5´GCCAACCGTGAAAAGATGAC  
reverse  5´ GAGGCATACAGGGACAGCAC, 95 bp. 
 All RT-PCR procedures were performed as described above. 
2.24 Statistical analysis 
All experiments were performed at least in triplicate. Values are expressed as means 
± standard deviation (SD). Statistical significance of differences was evaluated using 
Graph Pad Prism 4 software (Graph Pad Software, San Diego, CA, USA). Experi-
mental groups were compared by Mann-Whitney-U test. The level of significance is 
indicated with a single asterisk if p ≤ 0.05, two asterisks if p ≤ 0.01, and three aster-
isks if p ≤ 0.001. 
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3.1 Therapy with siRNA 
3.1.1 OEI-HD as a delivery vector 
3.1.1.1 Biophysical properties of OEI-HD/siRNA polyplexes 
Particle size and zeta potential of complexes formed at various polymer (OEI-HD, 
OEI-HD/Tf-PEG-OEI) to siRNA ratios prepared in HBG were determined using dy-
namic laser-light scattering (Table 3-I). Non-targeted OEI-HD/siRNA complexes tend 
to aggregate at a polymer/siRNA ratio of 0.5/1. In contrast, the targeted (10 weight % 
Tf conjugate) OEI-HD/siRNA formulations, showed no aggregation and sizes of about 
160 nm were achieved. For polymer/siRNA ratios of 1/1 as well as 2/1 (w/w) both, 
targeted and non-targeted OEI-HD/siRNA formulations appeared smaller in size and 
showed multimodal distribution (1 - 1000 nm). The low scattering intensity implies 
that predominantly smaller particles are present which is in accordance with findings 
seen by (Meyer at al. 2008). 
All standard OEI-HD/siRNA formulations had positive zetapotentials in the whole 
range tested (Table 3-I). In correlation with the increasing polymer/siRNA ratio, the 
charge of the particles increased continuously from +2.1±0.6 mV at the ratio 0.5/1 to 
+19.4±4.0 mV at the ratio 2/1. In contrast, Tf containing OEI-HD/siRNA formulations 
showed lower zeta-potential due to transferrin which also serves as a shielding agent 
(Kircheis et al. 2001). Using 10 weight % Tf and a polymer/siRNA (w/w) ratio of 0.5/1, 
particles were even slightly negatively charged. At higher ratios (up to 2/1) the Tf-
containing formulations showed increased zetapotentials of up to 11 mV.
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w/w ratio: 0.5/1 1/1 2/1 
Particle size (nm) 
OEI-HD 1193 ± 217 ** ** 
OEI-HD/ Tf* 155 ± 3 ** ** 
Zeta Potential (mV) 
OEI-HD + 2.1±0.6 + 11.5±2.5 + 19.4±4.0 
OEI-HD/ Tf* - 6.0±3.0 + 7.8±2.3 + 11.3±1.6 
Table 3- I: Particle size and zeta potential of OEI/siRNA formulations prepared in HBG. For-
mulations were prepared in HBG using the same concentration of siRNA as for in vivo appli-
cations; 10 µg siRNA in 40 µL HBG were used for measurement of particle size (Z-Average). 
For zeta potential, 1 mL 1 mM NaCl was added to the formulations prepared in HBG prior to 
measurement.   
* 10 weight % of OEI-HD are present as Tf-PEG-OEI conjugate. 
** no data presentation: particles appeared smaller and showed multimodal distribution (1 - 
1000 nm) - no in depth evaluation was performed. 
3.1.1.2 Preliminary in vivo studies 
Preliminary studies on dose finding revealed that acute toxicity of the polymer was 
significantly reduced if applied as polyplex in a polymer/siRNA ratio of 0.5/1. Seventy 
µg of free polymer killed mice within minutes after application. In contrast, animals 
receiving 70 µg OEI-HD complexed to siRNA even survived two applications at an 24 
h interval. We also carried out preliminary experiments using Tf-free complexes. OEI-
HD siRNA formulation was tested in a subcutaneous Neuro2A tumor mouse model 
using OEI-HD/siRNA formulations with polymer/siRNA ratio 0.5/1. Treatment by intra-
venous tail vein injection (2.5 mg formulated siRNA / kg applied 3 times at 3 days 
intervals) was started after subcutaneous tumors had reached a size of about 3 mm 
in diameter. Although transferrin free OEI-HD/siRNA complexes aggregate and there-
fore are less suitable for intravenous injection (see also Table 3-I), mice survived ap-
plications, but nevertheless showed only 40 % of Ran protein knockdown in tumors. 
The same conditions were chosen for analysis of in vivo potential of transferrin-
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shielded OEI-HD siRNA formulation, using 10 % Tf conjugate. Complexes with si-
CONTROL and untreated animals served as a control here. 
3.1.1.3 Tumor growth reduction in vivo 
Data representing the tumor growth following the systemic treatments described in 
2.13.1 are shown in figure 3-1.  
 
Fig. 3-1: Tumor growth reduction after systemic treatment of experimental animals by using 
Tf-targeted OEI-HD polyplexes of RAN siRNA compared with siCONTROL or non-treated A/J 
mice. Therapeutic application started after tumors had reached a size of about 125 mm3 and 
was repeated 3 times every 3 days. Tumor volume was measured using a digital caliper. 
Mean tumor volume and SD of five animals are shown for each day of tumor growth. Arrows 
indicate days of application. Data marked with asterisk are statistically significant relative to 
the non treated group as calculated by ANOVA (*, p < 0.05). 
Treatment with the RAN siRNA but not siCONTROL formulation significantly reduced 
the tumor growth. In addition, no obvious toxicity was observed in animals during the 
whole treatment period. Behavior of the animals and weights of mice were not signifi-
cantly different among the three groups of animals.  
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Fig. 3-2: Relative body weight of mice during systemic treatment. Mean values and 
SD of five animals are shown for each day.  
3.1.1.4 Blood cell and liver enzyme levels in treated mice 
Counting of blood cells and determination of various liver enzymes (figure 3-3) did 
not reveal any significant changes in hematology parameters nor in the activities of 
AST, ALT, AP, or GLDH. 
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Fig. 3-3: Biocompatibility (hematology and liver enzyme parameters) of Tf-targeted OEI-HD/ 
RAN siRNA or siCONTROL formulation, in comparison to non-treated animals. Whole blood 
samples were obtained from A/J mice 24 hours following the last of three injections and 
measured for blood counts (A) and liver enzymes (B). Data shown are mean levels ± SD out 
of 5-6 animals.  
3.1.1.5 Reduction of RAN protein expression in Neuro2A tumors  
The effects of systemically applied RAN siRNA or siCONTROL formulations were 
determined by western blot analysis of Ran protein in Neuro2A tumors and in livers of 
the same animals at 24 hours following the last application in comparison to non-
treated animals.  
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Fig. 3-4: Analysis of Ran protein expression in A/J-mice by western blot, following application 
of Tf-shielded RAN siRNA polyplexes, in comparison to siCONTROL polyplex-treated and 
non-treated animals. Protein levels (A) in Neuro2A tumors, and (B) in livers of the same ani-
mals. Protein expression levels of each sample were normalized for the expression of α-
tubulin set as 100 %. Samples were assessed one day after the last of three systemic appli-
cations. Data shown are mean ± SD. All data sets collected have a group size of five ani-
mals. Asterisks indicate statistical significance compared with the non treated group (*, p < 
0.05; ANOVA).  
The transferrin shielded RAN siRNA formulations reduced Ran protein expression by 
more than 80 % in tumors of treated mice as compared to non-treated animals. Ani-
mals treated with the analogous siCONTROL formulation did not show a significant 
Ran protein reduction in tumors (figure 3-4A). Ran protein expression in livers was 
not affected in any group (figure 3-4B). Transferrin free RAN siRNA formulations as 
additional control only led to knockdown of Ran protein of 40 % in comparison to 20 
% with transferrin-shielded Ran siRNA polyplexes (figure 3-5). 
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Fig. 3-5: Analysis of Ran protein expression in tumors of A/J mice following application of Tf-
shielded and unshielded Ran siRNA polyplexes in comparison to untreated animals (n = 3). 
3.1.1.6 Reduction of RAN mRNA expression in Neuro2A tumors 
In addition to Western blot results of Ran protein knockdown in tumors, qPCR anayl-
sis was performed to analyze the reduction of Ran mRNA. For normalization at first 
the four possible reference mRNAs glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH), ß-actin (ACTB), cytochrome c-1 (CYC1) and ATP synthase, beta subunit 
(ATP5ß) were analyzed for minimal variations across siRNA treatment using the ge-
Norm software (Vandesompele et al. 2002). The most stably expressed gene was 
ACTB, resulting in M = 0.277, M describing the average expression stability (lowest 
for the most stably expressed genes). The expression of ATP5B (M = 0.344), CYC1 
(M = 0.312) and GAPDH (M = 0.389) were less stable. Hence ACTB was the best 
candidate for normalization of Ran mRNA.  
Due to this results, for the following qPCR experiment a dual color approach was 
chosen to determine Ran mRNA and ACTB mRNA levels concurrently. Analysis 
showed a significant (p < 0.001) knockdown of Ran mRNA in Neuro2A tumors treated 
with Ran siRNA polyplexes, supporting the thesis of RNA interference (figure 3-6).  
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Fig. 3-6: Content of Ran mRNA in Neuro2A tumors measured by qPCR. All values are nor-
malized to ACTB content within the same samples. Values are mean ±SD out of 6 animals. 
Significance was determined using 1way ANOVA with Bonferroni´s Multiple Comparison; *** 
p < 0.001. 
3.1.1.7 Apoptosis in tumors of RAN siRNA treated mice 
In order to analyze the cellular consequences of siRNA-mediated silencing of the 
RAN gene expression, TdT-mediated dUTP biotin nick-end labeling (TUNEL) analy-
sis of treated tumor tissues was performed, which allows for the detection of apop-
totic cells. In order to corroborate the notion that this effect was specific to the tumor 
cells, liver tissue samples were TUNEL stained and likewise analyzed.  
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Fig. 3-7: Analysis of apoptosis in Neuro2A tumors (A) and liver (B) following application of Tf-
shielded RAN siRNA polyplexes compared to siCONTROL polyplexes or non-treated animals 
by TUNEL staining of 5 µm tissue sections. The apoptotic fraction was derived by counting 
the TUNEL-positive fractions (green) of 100 cells from up to 20 random fields in each tumor 
section. DAPI was used for nuclear counterstaining (blue). Upper part of the figure shows 
selected examples of staining demonstrating the average findings. Lower part shows the 
statistical evaluation of all fractions analyzed. Values are means from five animals per group 
± SD. Asterisk marks statistical significance compared with the non treated group (*, p < 
0.05).  
The number of apoptotic cells in the tumors treated with RAN-specific siRNA was 
increased to 12 % compared with non-treated animals (0.2 %) (figure 3-7A). Fur-
thermore, non-treated animals and animals treated with the siCONTROL formulation 
showed no significant increase in apoptotic cells within the tumors. In contrast to 
apoptosis in tumors, therapeutic RAN siRNA did not significantly affect the liver cells 
of the same animal (figure 3-7B). Neither the specific RAN siRNA nor the control 
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siRNA formulation changed the number of apoptotic cells within the liver as com-
pared to non-treated animals.  
3.1.2 OEI-HA10 as a delivery vector 
Due to preliminary in vitro data with siRNA on Neuro2A cells that led to promising 
knockdown and cytotoxicity data (unpublished data, Alexander Philipp and Arkadi 
Zinchenko), this vector was tested for its in vivo delivery potential similarly to OEI-
HD1 (see chapter 3.1.1).  
3.1.2.1 Acute toxicity of free OEI-HA10 polymer 
Polymer concentrations of 50 µg, 75 µg and 100 µg (per 20 g body weight, in 200 µl 
HBG) were intravenously injected up to three times every 24 h in BALB/c mice. Of 
these concentrations the latter (100 µg/20g) led to immediate sealing of the vein and 
was therefore not possible to apply. The two lower concentrations were possible to 
be applied even three times. Over the first two days of application animals appeared 
healthy and did not show any signs of acute toxicity, like loss in body weight. Not until 
the third application could necrotic tails be observed in animals treated with 50 and 
75 µg free OEI-HA10. Our hypothesis is that low concentrations of OEI-HA10 did not 
lead to immediate damage of the vein. However after repeated applications at the 
same injection site these injuries multiply, leading to necrosis. 
3.1.2.2 Lytic activity of free OEI-HA10 polymer 
In order to measure membrane destabilization activity of OEI-HA10, lytic activity was 
measured on erythrocytes. Freshly isolated murine erythrocytes (6000 erythrocytes / 
ml) were incubated with free polymer of final concentrations 0.01, 0.025, 0.05 and 0.1 
mg/ml in HBG (pH 7.4), containing 10% (v/v) FCS for 45 minutes at 37°C. For com-
parison, other polymers like L-PEI and OEI-HD1 that were tolerated well in vivo 
served as a control. While L-PEI and OEI-HD1 did not lead to more than 20 % eryth-
rocyte lysis even if applied in concentrations of up to 0.1 mg/ml, OEI-HA10 showed a 
strongly enhanced lytic effect. Already at concentrations of 0.05 mg/ml erythrocyte 
lysis of about 75 % was detected. 
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Fig. 3-8: Quantification of hemoglobin release at 450 nm, after incubation of OEI-HA10 
polymer with murine erythrocytes for 45 minutes at 37°C. 100% lysis refers to TritonX treat-
ment of erythrocytes. 
In summary, addition of the hexyl chain strongly increased the membrane destabilis-
ing activity of OEI. The toxicity of OEI-HA10 and the corresponding complexes 
seems to be related to the high membrane destabilizing activity of OEI-HA10. This 
leads to membrane blebbing and cell lysis.  
3.1.2.3 Erythrocyte aggregation induced by free OEI-HA10 polymer 
The influence of free OEI-HA10 polymer on erythrocyte morphology was analyzed by 
incubation of freshly isolated murine erythrocytes as described in 3.1.2.1. Aggrega-
tion was visualized by microscopy. No aggregation was detected with the analyzed 
polymer concentrations, however with higher concentrations of 0.05 and 0.1 mg/ml 
due to lysis almost no erythrocytes were detected.  
 
Fig. 3-9: Effect of OEI-HA10 polymer on erythrocyte aggregation. Murine erythrocytes were 
incubated with free polymers at different polymer concentration for 45 min at 37°C. Morphol-
ogy was visualized microscopically with a 51-fold magnification using a Axiovert 200 micro-
scope. 
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3.1.2.4 Acute toxicity of OEI-HA10 / Ran siRNA polyplexes 
If applied in a w/w ratio of 2 (5 mg OEI-HA10 / kg) in A/J mice animals did not survive 
for more than 30 minutes. Pathological analysis revealed indications of ischemic 
stroke in these animals (unpublished data) while all other organs did not show any 
macroscopically detectable changes. It might be worthwhile to mention that com-
plexes formed in a w/w ratio of 2/1 showed positive surface charges of about 13 mV, 
while complexes formed at w/w 1 had a negative zetapotential of about - 18 mV. With 
regard to pathological findings after systemic complex applications, a negative sur-
face charge seems to be much better tolerated in vivo than positively charged poly-
plexes. Importantly, the negatively charged complexes with a w/w ratio of 1 showed 
optimal transfection efficiency in vitro.  
In contrast, polyplexes formed with siRNA in a w/w ratio of 1/1 were tolerated well in 
A/J mice, even if applied three times every 24 h. No necrotic changes in tail tissues 
were detectable after polyplex applications.  
Since the positive charge of polyplexes is supposed to improve the stability of nucleic 
acids against degradation as well as the ability to penetrate into cells, the application 
of positively charged formulations is desired. For enhancement of tolerability of such 
polyplexes the block-copolymer pluronic F127 was introduced into formulations. Due 
to its amphiphilic character this copolymer displays surfactant properties and at con-
centrations above critical micelle concentration (CMC) these copolymers self-
assemble into micelles. Additionally, it is able to adsorb on hydrophobic areas and 
hydrophilize the surfaces.  
The tolerated dose of OEI-HA10 was possible to increase by formulating complexes 
together with pluronic F127 (w/w OEI-HA10 / F127 = 1). This led to formulations that 
were tolerated much better in vivo. Even a w/w ratio of OEI-HA10 / siRNA of 2 was 
tolerated with this mixture. Nevertheless, one out of six animals showed a paralysed 
left body side and died within 30 minutes following application. Macroscopic examina-
tion of the brain exhibited an polythrombotic stroke in this animal. Another animal 
showed necrotic tail tissue after complex application (unpublished data).  
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Polyplexes in a w/w of 1 (with and without pluronic F127) were tolerated well in all animals. 
Complexes could be applied three times, every 48 h without influencing appearance, behav-
ior or body weight of the mice. 
3.1.2.5 Tumor growth reduction after polyplex application in vivo 
Similarly to therapeutic studies described in chapter 3.1.1 with the polymer OEI-HD, 
8 week old female A/J mice bearing a subcutaneous Neuro2A tumor were treated 
with OEI-HA10 / Ran siRNA complexes or OEI-HA10 / Ran siRNA / pluronic F127 
complexes respectively.  
Treatment by intravenous tail vein injection (2.5 mg formulated siRNA / kg applied 3 
times at 2 days intervals) was started after tumors had reached a size of about 3 mm 
in diameter. Figures below show tumor growth curves of mice over time (figure 3-10 
A, B). Compared to animals without any treatment, mice receiving 3 applications of 
Ran siRNA complexed to OEI-HA10 in a w/w ratio of 1, showed reduced tumor 
growth already at day 2 after the first injection. In contrast, pluronic F127 conjugated 
complexes had no effect on tumor growth. 
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Fig. 3-10: Tumor growth reduction after systemic treatment of experimental animals by using 
OEI-HA10 polyplexes of RAN siRNA or non-treated A/J mice. Figure (A) displays results ob-
tained with OEI-HA10 complexes, whereas in figure (B) pluronic F127 in a w/w ratio of 1  was 
added to the OEI-HA10 complexes.  Therapeutic application started after tumors had 
reached a size of about 3 mm in diameter and was repeated 3 times every 2 days. Tumor 
volume was measured using a digital caliper. Animals were sacrificed 24 hours following the 
last application. Mean tumor volume and SD are shown for each day of tumor growth. Arrows 
indicate days of application. 
3.1.2.6 Liver enzyme levels in treated mice 
For determination of liver toxicity, activities of various liver enzymes was analysed 24 
hours following the last of three injections. None of the treated groups showed signifi-
cant differences in alkaline phosphatase (AP), aspartate or alanine transaminase 
(AST and ALT) or glutamate dehydrogenase (GLDH), indicating tolerability of com-
plexes. 
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Fig. 3-11: Liver enzyme activities of HA10 formulation, complexed with Ran siRNA in com-
parison to non-treated animals. Blood samples were obtained 24 hours following the last of 
three injections, plasma was separated and measured for liver enzyme activities. Data shown 
are mean levels ± SD of 5-6 animals. 
3.1.2.7 RAN protein expression in Neuro2A tumors 
The effects of systemically applied Ran siRNA formulations were determined by 
western blot analysis of Ran protein in Neuro2A tumors at 24 hours following the last 
application (as described in 3.1.2.5) in comparison to non-treated animals. Ran pro-
tein content was not affected with any of the applied OEI-HA10 formulations as 
shown in figure 3-12. 
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Fig. 3-12: Analysis of Ran protein expression in Neuro2A tumors in A/J-mice by western blot, 
following application of Ran siRNA polyplexes, in comparison to non-treated animals. Protein 
expression levels of each sample were normalized for the expression of α-tubulin set as 100 
%. Samples were assessed one day after the last of three systemic applications. Data shown 
are mean ± SD of at least 5 animals.  
3.1.2.8 Reduction of RAN mRNA expression in Neuro2A tumors 
In addition to Western blot results of Ran protein knockdown in tumors, qPCR anayl-
sis was performed to analyze the reduction of Ran mRNA. For normalization at first 
the four possible reference mRNAs glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH), ß-actin (ACTB), cytochrome c-1 (CYC1) and ATP synthase, beta subunit 
(ATP5ß) were analyzed for minimal variations across siRNA treatment using the ge-
Norm software (Vandesompele et al. 2002). The most stably expressed gene was 
ACTB, resulting in M = 1.599, M describing the average expression stability (lowest 
for the most stably expressed genes). The expression of ATP5B (M = 3.525), CYC1 
(M = 1.740) and GAPDH (M = 1.636) were less stable. Hence ACTB was the best 
candidates for normalization of Ran mRNA.  
The following dual color qPCR with ACTB as housekeeping gene revealed no knock-
down of Ran mRNA with any of the complexes in tumor tissues, confirming previous 
findings on Ran protein levels by western blot analysis (see 3.1.2.6). 
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Fig. 3-13: Detection of Ran mRNA content in tumors of A/J mice, 24 h after the last of three 
applications. Levels are normalized to ACTB mRNA content. Data are mean levels ± SD from 
6 animals per group. 
3.1.2.9 Histopathological analysis of tumors 
To analyze the morphology of treated and untreated Neuro2A tumors, 24 h after the 
last of three injections (see chapter 3.1.2.5) tumors were explanted and embedded in 
paraffin. After cutting into 5 µm sections and staining with hematoxylin and eosin, pic-
tures were taken for histopathological analysis. In case of OEI-HA10 / RansiRNA 
treated tumors changes in the histology of tumors were visible. Parts of the tumor 
tissue showed necrotic areas, being in line with the findings on tumor growth inhibi-
tion. No such changes were found for the pluronic F127 modified complexes. 
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Fig. 3-14: Histology of Neuro2A tumors after OEI-HA10 therapy. Paraffin embedded sections 
of untreated (A), OEI-HA10 complex treated (B), OEI-HA10 formulations with pluronic F127 
in a w/w ratio of 1 (C) and 2 (D) were stained with hematoxylin and eosin. In case of OEI-
HA10 polyplex treatment necrotic areas can be detected. 
3.1.2.10 OEI-HA10 / siRNA complexes formed with helper lipids 
In the previous chapters it was shown that masking of hydrophobicity of HA10 by in-
corporation of lipophilic agents could increase the tolerability of positively charged 
formulations. A possible reduction of efficiency represents, however, a big hurdle. The 
incorporation of another lipophilic molecule dioleoyl-phosphatidylethanolamine 
(DOPE) led even to increase in in vitro transfection efficiency of formulations and cer-
tain decrease of the toxicity in vitro (Arkadi Zintchenko and Alexander Philipp, unpub-
lished data). Therefore, in a next step the in vivo compatibility of such formulations 
was tested.  
A  
C 
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3.1.2.11 Acute toxicity of OEI-HA10 / DOPE  
Uncomplexed polymer / DOPE (w/w: 2/1) were injected intravenously into 3 month 
old female A/J mice in the concentrations 2.5 mg polymer / kg and 5.0 mg polymer / 
kg. Animals did not survive any of these concentrations and died within one hour due 
to hemorrhagic extravasation in the intestine and brain liquor as detected by macro-
scopic evaluation. 
3.1.2.12 Acute toxicity of OEI-HA10 / DOPE / siRNA complexes 
In a next step OEI-HA10 was mixed with the lipid DOPE and subsequent complexa-
tion with siRNA. Three different concentrations were analyzed for tolerability, namely:  
2.5 mg siRNA / kg complexed with 5.0 mg OEI-HA10 / kg and mixed with 10.0 mg 
DOPE / kg (surface charge of ~ +30 mV) 
2.5 mg siRNA / kg and the reduced amounts of 2.5 mg OEI-HA10 and 5.0 mg DOPE  
(surface charge of ~ - 40 mV) 
The siRNA amount was decreased to 1.25 mg / kg, complexed with 3.75 mg OEI-
HA10 and mixed with 7.5 mg DOPE / kg  (surface charge of ~ +30 mV) 
The incorporation of DOPE did not enhance tolerability, as all animals died within one 
hour after intravenous tail vein injection due to hemorrhagic extravasation in intestine 
and brain liquor (data not shown). Unlike pure HA10 formulations, even negatively 
charged polyplexes became toxic.   
DOPE is known to show membrane destabilizing properties. This could be the origin 
of high toxicity of such formulations in vivo. Partial substitution of DOPE by colipids 
might be able to stabilize the lipid membrane and, therefore, improve the toxicity pro-
file of the formulations. Cholesterol, dioleoyl-phosphatidylcholine (DOPC) and di-
palmitoyl-phosphatidylcholine (DPPC) were introduced as colipids at different ratios 
to DOPE.  
Unfortunately, all OEI-HA10 formulation mixtures tested in the PhD thesis showing no 
toxicity in vivo did not show efficiency in mRNA knockdown in cell culture experi-
ments.  
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3.2 Gene Delivery with pDNA 
3.2.1 Influence of delivery vectors on toxicity and transfection efficiency 
3.2.1.1 DNA condensation 
To study polyplex formation between pDNA and polymers with or without incorpora-
tion of transferrin-conjugates at different w/w ratios, ethidium bromide exclusion as-
says were performed (figure 3-15). The condensation efficiencies of L-PEI, OEI-HD 
and lt-OEI-HD1.2 were comparable. The experiment furthermore showed that ex-
change of 25 weight % polymer through the corresponding transferrin-conjugate had 
no negative effect on condensation properties for any of the analyzed polymers. 
 
Fig. 3-15: DNA condensation efficiency of studied by ethidium bromide exclusion assay for 
OEI-HD1 (A), lt-OEI-HD1.2 (B) and L-PEI (C). Increasing polymer / pDNA ratios (w/w) were 
analyzed either without or with incorporation of 25 weight % transferrin conjugate (Tf-PEI25 
for L-PEI and Tf-PEG-OEI-HD1 for OEI-HD1 and lt-OEI-HD1.2). All experiments were per-
formed in quadruplicate. 
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3.2.1.2 Stability against Heparin Displacement 
To evaluate polyplex stability against displacement of pDNA by competing polyan-
ions, the polyplexes were challenged with free heparin (figure 3-16). Heparin 
amounts as low as 0.5 U displaced DNA from the complex in the case of OEI-HD and 
lt-OEI-HD1.2. OEI-HD and lt-OEI-HD1.2 transferrin complexes showed a slightly de-
creased stability against heparin displacement. With these polyplexes, free plasmid 
DNA was observed at heparin concentrations of 0.25 U and above. In contrast, L-PEI 
/ transferrin polyplexes released the pDNA just at heparin concentrations of 0.75 U 
(at about 1 U without transferrin (Germershaus et al. 2008)). 
 
Fig. 3-16: Heparin displacement assay using L-PEI, OEI-HD and lt-OEI-HD1.2 complexes 
with and without transferrin. Complexes were incubated for 30 minutes with increasing hepa-
rin concentrations. Free plasmid is shown as a control on the left. 
3.2.1.3 Size und Zetapotential 
The ability of L-PEI, OEI-HD1 and lt-OEI-HD1.2 polyplexes to condense pDNA was 
also evaluated by particle size and zetapotential measurements. Hydrodynamic di-
ameters of OEI-HD1 and lt-OEI-HD1.2/pDNA complexes at w/w ratios ranging from 
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0.5 to 1.4 showed a similar trend of decreased particle size with increased w/w ratios 
(Figure 3-17). The average particle size is less than 250 nm. Particles sizes tend to 
be increased after addition of Tf-conjugates, though differences were not significant 
for L-PEI, OEI-HD or lt-OEI-HD1.2.  
As expected, addition of the shielding moiety Tf reduced the zetapotential of com-
plexes. 
 
Fig. 3-17: Size and zetapotential of polyplexes formed with L-PEI (A) , OEI-HD1 (B) and lt-
OEI-HD1.2 (C) with and without addition of Tf-conjugate respectively. Values representing 
size by number are displayed as bars, values representing ζ potential are displayed as dots 
and connected with a line. All data shown are mean values ± SD from three measurements. 
3.2.1.4 Transfection efficiency in vitro 
Plasmid DNA (pCMVLuc) was complexed with L-PEI, OEI-HD or lt-OEI-HD1.2 re-
spectively at w/w ratios of 0.5 to 1.4 to examine the transfection efficiency (figure 3-
18A) and metabolic activity in vitro (figure 3-18B). The effect of transferrin incorpora-
tion as shielding and targeting moiety was analyzed concurrently. As expected, trans-
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fection efficiency increased with increasing polymer ratio. Best results regarding 
transfection efficiency were obtained with the polymer/DNA ratio 1.4/1. 
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Fig. 3-18: In vitro transfection efficiency (A) and cell viability after treatment with polyplexes 
(B) of polyplexes with pCMVLuc. Transfection was carried out on Neuro2A cells and for both 
assays cells were analyzed 24 hours following transfection. For the cell viability assay all 
values were normalized against untreated cells (white bar), which were set for 100 % cell 
viability.  
3.2.1.5 Acute toxicity of polymers and polyplexes in vivo 
Free polymers L-PEI (22 kDa), OEI-HD1 and lt-OEI-HD1.2 were applied intrave-
nously into A/J mice (2.5 mg/kg in HBG; total volume 200 µl) and livers of these ani-
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mals were examined for histopathological changes 24 hours after administration. In 
animals receiving L-PEI a microvesicular fatty liver was observed, similar to patho-
logical finding described for acute and chronic intoxications (Ogris et al. 2007) (figure 
3-19). 
In contrast, after application of OEI-HD and lt-OEI-HD1.2 livers showed no histopa-
thological changes. Images in figure 3-19B show livers of A/J mice 24 hours after i.v. 
injection of transferrin shielded pDNA complexes formed with the same polymers. 
Here no changes were observed with any of the used formulations. 
 
Fig. 3-19: Liver histology after administration of free polymers (A) and transferrin shielded 
pDNA polyplexes (B). Livers were explanted 24 hours after i.v. application of polymers and 
polyplexes (w/w 0.8/1) respectively, embedded in paraffin and cut into 5 µm thick slices. Im-
ages were taken after hematoxylin and eosin staining in a 32-fold magnification using an Ax-
iovert 200 microscope, equipped with an Infinity 2 CCD camera. 
Furthermore, the influence on body weight was measured for application of poly-
plexes. As shown in figure 3-20 complexes without transferrin shielding were less 
tolerated than those containing 25 % (w/w) transferrin-conjugate, which is in good 
correlation not only with the histopathological findings shown in figure 3-19 but also 
with previous findings for PEI by (Ogris et al. 1999).  
3 Results 58 
 
 
Fig. 3-20: Influence of systemic polyplex application on body weight of A/J mice. Change in 
body weight was measured 24 hours after injection of complexes without (A) and with (B) 25 
% (w/w) transferrin-conjugate incorporated. Values represent mean levels ± SD of 3-5 ani-
mals. Differences between a treated group and the untreated control group a marked with an 
asterisk; * p<0.05, ** p<0.01, ***p<0.001. 
3.2.1.6 Transfection efficiency in vivo 
For in vivo testing of polyplexes the three polymer to pDNA ratios (w/w) 0.5/1, 0.8/1 
and 1.4/1 were prepared. Complexes containing 2.5 mg plasmid / kg mouse in a total 
volume of 250 µl were applied once into the tail vein. Twenty four hours later animals 
were sacrificed, organs were explanted and analyzed for luciferase expression using 
a tube luminometer. L-PEI polyplexes in a w/w ratio of 0.8/1 served as a control. In 
the series of transferrin free complexes L-PEI showed high transfection efficiencies in 
every organ with by far the highest values in the lung. This effect of L-PEI is com-
monly known (Zou et al. 2000) and is generally deemed acceptable as a side effect 
occurring together with good tumor transfection. In contrast, gene expression with 
OEI-HD and lt-OEI-HD1.2 was lower in all organs. As primarily the tumor is the target 
for gene expression this is a favored result. However, without transferrin, also in tu-
mors only lt-OEI-HD1.2 in a w/w ratio of 1.4/1 reached levels of L-PEI (w/w 0.8/1) 
(figure 3-21A). For the series of polymer/transferrin-conjugate polyplexes, almost no 
differences between the groups was seen in any organ analyzed (figure 3-21B).  
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Fig. 3-21: Gene expression in A/J mice 24 hours after intravenous tail vein injection. Com-
plexes were either used without (A) or with incorporation of 25 weight % of transferrin-
conjugate (B). All values represent mean and SD data from 5-6 animals. 
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3.2.2 Influence of CpG motifs in pDNA on transfection efficiency 
The impact of CpG motifs on transfection efficiency as well as the impact of manufac-
ture-related genomic DNA impurities after normal and hydrodynamic tail vein injection 
was investigated in the following part.  
3.2.2.1 Biophysical properties of L-PEI plasmid complexes 
Hydrodynamic diameters of complexes formed at various polymer to pDNA (N/P) ra-
tios prepared in HBG were determined using photon correlation spectroscopy (figure 
3-22). All complexes showed particle sizes within the same range of 120 to 150 nm, 
revealing no differences in complexation characteristics. Complex sizes were 147.0 ± 
3.7 nm for pCpGLuc and 153.4 ± 4.4 nm for pCpGLuc ccc at N/P 5, 135.7 ± 9.4 nm 
and 138.4 ± 5.3 nm for N/P 6, 150.7 ± 5.6 nm and 119.3 ± 29.3 nm at N/P 9 for 
pCpGLuc and pCPGLuc ccc, respectively.  
Zeta potential measurements indicated no major differences between complex 
charges either (figure 3-22). Zeta potentials of + 30 to + 40 mV for non-shielded L-
PEI / pDNA particles are in good correlation with earlier observations made with this 
polymer in 5 % glucose solution (Zou et al. 2000). 
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Fig. 3-22: Surface charge (zeta potential, left y-axis) and hydrodynamic diameter (size, right 
y-axis) as a function of the N/P ratio. Complexes were prepared in HBG. Values shown rep-
resent mean ± SD of three measurements.  
3.2.2.2 L-PEI based pDNA delivery in Neuro2A cells 
The pDNA was complexed with linear polyethylenimine (L-PEI) at different N/P ratios 
commonly used for in vivo transfection. Transfection was analyzed first in vitro on 
Neuro2A cells for its efficiency at the three time points (i) 24 h, (ii) 48 h and (iii) 72 h.  
Luciferase expression was increased with the supercoiled (ccc) grade plasmid com-
pared to research grade (RG) plasmid for both plasmids with both N/P ratios at any 
time point. Interestingly the vector containing CpG motifs, pEGFPLuc, showed con-
siderably higher transfection efficiency than the pCpGLuc plasmids (figure 3-23A). 
Cell viability was influenced similarly by the two analyzed plasmids, showing reduced 
viability of down to 75 % for all plasmids at N/P 9 at 24 hours after transfection, how-
ever completely recovering over the following 24 hours, showing results comparable 
with untreated control cells (figure 3-23B). 
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Fig. 3-23: Transfection efficiency (A) and cell viability (B) over a period of three days. Both 
experiments were performed on Neuro2A cells. Results display the mean value and standard 
deviation out of 6 measurements.  
3.2.2.3 In vivo transfection efficiency after standard i.v. application 
The three different N/P ratios were tested in vivo in BALB/c mice (n=3-4). Animals 
received 200 µl of complexes, containing 50 µg plasmid, via the tail vein. Transfection 
efficiency was measured over time by a CCD camera (XENOGEN IVIS system) 10 
minutes after i.p. luciferin injection. For calculation of efficiency a region of interest 
was drawn over the lung area and luminescence signals integrated from this area 
were followed over time (figure 3-24). 
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Minor differences in transfection efficiency between pEGFPLuc and pCpGLuc poly-
plexes at N/P 6 were monitored, while no significant differences were obtained be-
tween the two purification grades, whatever plasmid was used. In contrary starting 
with similar transfection results for N/P 6, the efficiency of the pCpGLuc ccc plasmid 
increased with increasing N/P ratio compared to the pCpGLuc RG plasmid polyplex.  
This shows that the N/P ratio of complexes as well as the purity of plasmid used in-
fluences transfection efficiency in vivo.  
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Fig. 3-24: In vivo transfection efficiency of pCpGLuc and pEGFPLuc. (A) displays represen-
tative pictures as seen by the CCD camera 6 and 72 hours after systemic transfection. In (B) 
lung values of all animals are plotted against time and displayed as mean values ± SD.. 
3.2.2.4 Cytokine expression after i.v. polyplex application 
In order to examine the possible immunomodulatory activity of our plasmids, we 
measured expression of 40 cytokines. Cytokine levels were detected in plasma 6 h 
after injection of plasmid complexes at an N/P ratio of 6. Diagrammed are only cyto-
kines showing measurable distinctions between the non treated control and the poly-
plex treated groups. The diagrammed cytokines are all associated with inflammatory 
processes. However, no differences were found between cytokine expression levels 
after application of RG or ccc plasmid complexes, indicating that the differing effect in 
transfection efficiency had no influence on cytokine levels of treated animals.  
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Fig. 3-25: Cytokine and chemokine expression in mouse plasma, 6 h after polyplex applica-
tion with pCpGLuc in RG or ccc quality. Values represent mean levels out of 6 animals ± 
standard deviation. The control group was not treated. 
3.2.2.5 In vivo transfection efficiency after hydrodynamic tail vein ap-
plication 
The influence of CpG motifs as well as of remaining bacterial genomic DNA was ana-
lyzed after hydrodynamic delivery of plasmids to the liver. Rapid injection of a rela-
tively large volume of DNA solution (25 µg / 2.5ml) is known to be efficient, safe and 
induce long term gene expression (Alino et al. 2003, Zhang et al. 2000, Miao et al. 
2001). The influence of a carrier can be excluded by this way of application. Lucifer-
ase gene expression was measured by in vivo imaging using an IVIS 100 (Caliper 
LifeSciences) over a time period of 3 weeks. 
Only at the first measurement, 24 hours following the hydrodynamic application, 
could differences be observed between the two purification rates. From day two on 
diverse expression levels were only detectable between the CpG-containing versus 
the CpG-free plasmid. While the CpG-free plasmids (pCpGLuc RG and pCPGLuc 
ccc) showed a relatively constant level of gene expression over a time period of 2 
weeks, gene expression levels in CpG-containing plasmid treated animals decreased 
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dramatically starting already at day two. After 16 days values started to align and no 
more differences were detectable 3 weeks after the injection.  
 
Fig. 3-26: Luciferase gene expression in livers of BALB/c mice as detected by a CCD cam-
era 10 minutes after i.p. luciferin injection. 
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4.1 Therapy with siRNA 
4.1.1 OEI-HD as a delivery vector 
High molecular weight polyethylenimine (PEI) is a polycationic carrier for nucleic ac-
ids mediating high DNA transfection activity in vitro and in vivo (Boussif et al. 1995, 
Zou et al. 2000). In vivo application however is limited by significant toxicity (Chollet 
et al. 2002) and lack of biodegradability of the polymer. In order to develop polyca-
tionic carriers that are as effective as the gold standard PEI but less toxic and biode-
gradable, we and others developed new polymers based on crosslinking of low mo-
lecular weight oligoethylenimines (OEI) using various degradable linkages (Kloeckner 
et al. 2006-1, Kloeckner et al. 2006-3, Gosselin et al. 2001, Forrest et al. 2003, Kim 
et al. 2005, Hoon et al 2007, Lee et al. 2007). In our studies, a propionamide-
crosslinked PEI derivative (OEI-HD) was identified as gene transfer carrier with com-
parable efficiency as PEI but lower toxicity (Koeckner et al. 2006-3). Interestingly, 
unlike PEI (Hassani et al. 2005, Grayson et al. 2006), this polymer was found to be 
also effective for siRNA delivery in vitro (Tarcha et al. 2007).  
The studies described in this work extended the investigations with OEI-HD formu-
lated siRNA from in vitro cell culture to the therapeutically more relevant systemic in 
vivo application in tumor-bearing mice. To convert OEI-HD polyplexes into biocom-
patible particles which are expected to be shielded from undesired interactions with 
blood components, our laboratory synthesized and incorporated transferrin-
polyethylenglycol-OEI-HD conjugates into the siRNA polyplexes (Alexander Philipp, 
PhD thesis in progress). Similar strategies have been previously successfully applied 
by us and others for systemic tumor targeting to the transferrin receptor with DNA 
lipoplexes (Xu et al. 1999), DNA polyplexes (Ogris et al. 1999, Kursa et al. 2003) and 
more recently also siRNA /cyclodextrin-conjugate complexes (Hu-Lieskovan et al. 
2005).  
Optimized transferrin-conjugate/ OEI-HD/ siRNA formulations displayed efficient 
knockdown efficiency in Neuro2A-EGFPLuc cells which was comparable with non-
shielded formulations. Notably, in contrast to non-shielded formulations, transferrin-
modified formulations had reduced zeta potential and did not aggregate at low w/w 
ratios, thus appearing more suitable for in vivo applications.  
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For evaluating the therapeutic potential of the new formulation in vivo, the delivery 
potential of siRNA against RAN in the Neuro2A tumor model was tested in this thesis. 
RAN encodes a small Ras-related GTPase protein (Dasso 2001, Mattaj and Engl-
meier 1998, Quimby and Dasso 2003) that is involved in many aspects of nuclear 
function, such as transport into and out of the nucleus, cell cycle control and post-
mitotic nuclear assembly, required for cell survival. The Ran protein was recently 
identified from an RNAi based screen as possible target in cancer therapy (Morgan-
Lappe et al. 2007). A short time later a coherency between Ran overexpression and 
tumor tissue as well as apoptosis due to Ran silencing was demonstrated in vitro (Xia 
et al.  2008). OEI-HD/ Ran siRNA formulations were evaluated in our laborator in vi-
tro and showed an antitumor effect in cell culture (A. Phillip and J. Pelisek). 
In the current thesis, for systemic application transferrin-free as well as transferrin-
shielded OEI-HD/ Ran siRNA formulations were analyzed. Though unshielded com-
plexes tend to aggregate and therefore are less suitable for systemic application 
(Dash et al. 1999, Ogris et al. 1999, Dash et al. 2000), these complexes were toler-
ated as well as the shielded complexes in vivo (50 µg siRNA formulated at 0.5/1 ratio, 
applied intravenously three times at three day intervals). However application of Tf-
shielded OEI-HD/ Ran siRNA formulations in the Neuro2A mouse tumor model re-
sulted in a more than 80 % knockdown of RAN protein expression in tumors as com-
pared to non treated control animals and application of unshielded OEI-HD /Ran 
siRNA formulations only led to about 40 % Ran protein knockdown. Mice treated with 
the control siRNA formulations did not show significantly reduced Ran expression. 
The higher efficacy of Tf-shielded particles can not only be explained by the reduced 
aggregation potential leading to increased circulation times and improved tumor up-
take by EPR (enhanced permeation and retention) effect (Iyer et al. 2006). We hy-
pothesize that in addition transferrin-mediated active transport into the tumor cells 
improves RAN knockdown, as Neuro2A tumor cells are known to over-express Tf-
receptors on the cell surface (Kircheis et al. 2001, Kircheis et al. 1999, Bartlett and 
Davis 2008).  
Efficient Ran protein knockdown of Tf-containing formulations was in a next step con-
firmed on mRNA level by quantitative RT-PCR, giving evidence that knockdown is 
mediated by RNAi. Furthermore, the knockdown triggered apoptosis up to 12 % in 
Ran siRNA treated tumors, which was not observed in the control groups. The in-
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crease in apoptosis was tumor-specific. This was demonstrated by analysis of liver 
cells of the same animal that did not reveal any increase in the number of apoptotic 
cells. Tf-shielded OEI-HD/ RAN siRNA formulations were also able to significantly 
slow down the tumor growth, which is in good correlation with the findings of protein 
and mRNA knockdown as well as apoptosis. At this point it has to be mentioned that 
analyses of blood cells, liver enzymes in plasma, as well as body weight of mice 
showed no signs of toxicity, giving evidence that the complexes were well tolerated 
by the animals. However the treatment so far did not lead to the cure of mice. Ex-
periments extending the number of injections of RAN siRNA polyplexes, work with 
different delivery vectors or siRNA directed against a different target and/or combina-
tion with chemotherapy will be future directions to strengthen the therapeutic potency.   
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4.1.2 OEI-HA10 as novel delivery vector 
In an attempt to further optimize in vivo Ran siRNA knockdown after systemic com-
plex application, a new delivery polymer, OEI-HA10, was used. In cell culture this 
polymer displayed even better results regarding knockdown and toxicity than OEI-HD 
and was therefore seen as a promising candidate for further in vivo studies (unpub-
lished data, Alexander Phillip, Arkadi Zintchenko). For OEI-HA10 800 kDa sized oli-
goethyleneimine was modified with hexylacrylate chains to improve hydrophobicity 
and thereby the membrane interaction potential. Due to their small size, renal excrea-
tion might be possible for these particles. Chronic side effects due to accumulation in 
the body therefore can be excluded. In contrast, in OEI-HD OEIs are crosslinked to a 
longer sized polymer where first degradation of the amid linker formation had to take 
place until fragments can be excreted.  
First experiments on acute toxicity in vivo revealed that OEI-HA10 has a very narrow 
therapeutic window where higher doses lead to necrotic tails, ischemic strokes or 
hemorrhagic extravasations in brain and intestine. Erythrocyte lysis assays were per-
formed for OEI-HA10, OEI-HD and L-PEI as a control polymer, to investigate hemo-
lytic effects of the polymers. Results showed that OEI-HD and L-PEI were tolerated 
well, while already low concentrations of OEI-HA10 showed particular high lysis val-
ues. The coherency of hemolysis in vitro and in vivo toxicity has already been stated 
by (Moreau et al. 2002) and indicates a potential reason for the detected side effects. 
Using Ran siRNA complexes in a w/w ratio of 1 with 2.5mg siRNA / kg systemic ap-
plication however was tolerated up to three times, with one injection of this dose 
every second day. With this dosing schedule a significant reduction in tumor growth 
was observed. However, the formulation did not lead to Ran protein or Ran mRNA 
knockdown. Histopathological analysis of tumor tissues revealed necrotic areas in 
OEI-HA10 / Ran siRNA treated tumors. With regards to the results obtained for Ran 
protein and mRNA knockdown it can be hypothesized that not Ran siRNA downregu-
lation but toxicity of OEI-HA10 polymer itself was responsible for the reduced tumor 
growth as it was already described for other polycationic vectors (for example by 
Dufes 2005). For OEI-HA10 this finding can be explained with the hydrophobicity of 
OEI-HA10 that allows the polymer to strongly interact with cell membranes. Probably 
due to passive accumulation into the permeable tumor vasculature, based upon the 
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enhanced permeability and retention (EPR) effect (Aoki et al. 2001), OEI-HA10 was 
able to reach the tumor tissue, interact with tumor cell membranes or damage tumor 
vessels and by this lead to necrosis as shown in 3.1.2.9. A similar effect of necrosis 
after treatment with vascular disrupting agents was described in (Siemann et al. 
2005). Looking back at the results obtained with free OEI-HA10 in an erythrocyte ly-
sis assay, were up to 75 % erythrocyte lysis was detected, this effect is likely due to 
the membrane destabilizing effect of OEI-HA10. Addition of hexylacrylate to OEI was 
thought to improve transfection efficiency compared to OEI due to a higher mem-
brane interaction potential. However, this property needs to be thoroughly balanced 
to avoid interaction with erythrocyte membranes leading to hemolysis or lysis of 
blood vessel membranes leading to hemorrhagic extravasations. 
To enhance tolerability as well as efficiency polyplexes were prepared in the pres-
ence of pluronic F127, a member of the poloxamer family. This amphiphilic block-
copolymers, consisting of hydrophilic polyethylene oxide and hydrophobic polypro-
pylene oxide blocks, were reported as promoting drug penetration across different 
biological membranes like cell-membranes (Kabanov et al. 1992, Slepnev et al.  
1992) and the blood-brain barrier (Kabanov et al. 1989). By mixing with OEI-HA10 
hydrophobic hexyl chains of OEI-HA10 were thought to interact with hydrophilic parts 
of pluronic and by this reducing the hydrophobicity (and toxicity) of complexes. For 
therapeutic studies on Ran mRNA knockdown with OEI-HA10 in Neuro2A tumor 
bearing A/J mice, polyplexes with and without the incorporation of pluronic F127 were 
applied systemically. Administration of pluronic containing particles was tolerated up 
to a w/w ratio of 2 (6.25 µg OEI-HA10 / kg), while complexes without pluronic could 
only be administered up to a w/w ratio of 1 (3.1 µg OEI-HA10). However only applica-
tion of polyplexes without pluronic led to significantly reduced tumor growth, indicat-
ing that pluronic not only improved tolerability but in the same step reduced effi-
ciency.  
Therefore, we tried to find a lipid that is also able to reduce OEI-HA10’s hydrophobic 
character, however only down to a point where an effective membrane interaction 
potential still persists. To reach this goal, different neutral lipids, varying in their hy-
drophilic-lipophilic balance (HLB) were formulated together with OEI-HA10 and Ran 
siRNA and analyzed for their acute toxicity potential. Complexes formed with diole-
oylphosphatidylethanolamine (DOPE) and cholesterol showed reduced tolerability 
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compared to lipid free OEI-HA10 polyplexes. Dipalmitoylphosphatidylcholine (DPPC) 
in contrast needed to be formulated together with DOPE as a helper lipid to get toler-
ated by the animals, whereas Dioleoylphosphatidylcholine (DOPC) on its own was 
able to form tolerable complexes with OEI-HA10 and siRNA. However, none of the 
complexes that were tolerated in the first acute in vivo toxicity study showed any 
knockdown efficiency in cell culture (A. Philipp, unpublished results). These findings 
signify that further improvement of this vector is necessary to find complex formula-
tions that are not only well tolerated in vivo but also mediate efficient transport of 
siRNA into the desired cells. Possible alternatives might be  
(i) the reduction of hydrophobic units in the OEI-HA polmer 
(ii) the surface modification of OEI-HA10 complexes with neutral fragments like e.g. 
transferrin to provide secure transport within the blood stream 
(iii) or as an improvement on the second idea, modification of the complex surface 
with acid-labile PEG chains similar to (Knorr et al. 2008) is feasible. Here PEG would 
act as a neutral surface charge agent for secure blood circulation. Due to the EPR 
effect, polyplexes would be transported to the tumor tissue. As tumor tissue is known 
to have a higher pH than healthy tissue (Thistlethwaite et al. 1985, Vaupel  et al. 
1989, Gerweck et al. 1996, Wike-Hooley et al. 1997), PEG chains here would be 
separated and leave behind the hydrophobic polymer. Indeed, the hydrophobicity is a 
clear advantage as it might lead to an increased uptake into the tumor cells or into 
vascular endothelial cells within the tumor. Here OEI-HA10 could act as vascular dis-
rupting agent (VDA), resulting in tumor necrosis as it did in 3.1.2.9. The future poten-
tial of this therapy approach can be appraised by the fact that a number of VDAs are 
already tested in clinical trials (Hinnen and Eskens 2007). 
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4.2 Gene Delivery with pDNA 
4.2.1 Influence of delivery vectors on toxicity and transfection efficiency 
PEI is one of the most potent synthetic vectors used for gene delivery. However, es-
pecially in vivo its utilizability is limited due to toxic effects. These toxic effects are 
caused by (i) the huge amount of positive charges, leading to complex-mediated ag-
gregation with cellular blood components, especially erythrocytes, and through this to 
pulmonary embolism (Ogris et al. 1999). (ii) Chronic toxicity can be observed due to 
lack of biodegradability, leading to accumulation in the liver which itself leads to mi-
crovesicular fatty liver (Ogris et al. 2007). Both effects represent major hurdles for its 
in vivo use. 
To date a major challenge is to create a synthetic vector which combines efficient 
gene delivery and minimal in vivo toxicity (Kloeckner et al. 2006-2, Forrest et al. 
2003, Fischer et al. 1999). The main purpose of the study presented herein was to 
analyze the influence of the structure of two different polycationic synthetic delivery 
vectors on transfection efficiency and toxicity especially in vivo. Linear PEI (22kDa) 
served as a gold standard concerning transfection efficiency in all experiments. The 
two studied vectors only differed in their potential to be degraded into smaller parti-
cles under physiological conditions. As described in chapter 4.1.1 and by (Tarcha et 
al. 2007), OEI-HD consists of 800 Dalton OEI crosslinked by amid bonds, which are 
slowly degraded in vivo. After biodegradation only low molecular weight fragments 
are left over, which are well below the excretion limit of the kidneys. Synthesis of lt-
OEI-HD1.2 was similar to that of OEI-HD but reaction took place at a lower tempera-
ture, thus avoiding aminolysis of ester bonds (Kloeckner et al. 2006-3). This results in 
a much faster in vivo degradation by esterases.  
Experiments on in vitro transfection efficiency were carried out at different plasmid / 
polymer w/w ratios. Furthermore, the effect of incorporation of 25 weight % Tf-
conjugate as shielding and targeting moiety was analyzed. Transfection efficiency 
increased with increasing polymer/DNA ratio for polyplexes with and without transfer-
rin. The highest transfection efficiency was reached by using the polymer/DNA ratio 
of 1.4/1.  Analysis of the biophysical characteristics of the polyplexes showed similar 
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results regarding DNA condensing ability (with and without the incorporation of a Tf-
conjugate) and virtually similar results on stability against heparin displacement.  
In vivo toxicity studies with the free polymers showed that the biodegradable poly-
mers were much better tolerated than L-PEI. A dosage that leads to microvesicular 
fatty liver with L-PEI did not show any signs of liver toxicity with OEI-HD or lt-OEI-
HD1.2. However, it turned out that a w/w ratio of 1.4 (using 2.5 mg pDNA / kg) marks 
the LD50 dose for OEI-HD. By incorporation of transferrin as a shielding vector no 
histopathological changes in the liver were observed after intravenous injection of 
Tf/L-PEI-complexes. Similarly, incorporation of transferrin also lead to better tolerabil-
ity of OEI-HD and lt-OEI-HD1.2, regarding weight loss of animals after polyplex injec-
tions. Similar to in vitro transfection results, transfection efficiency in vivo increased 
with increasing w/w ratios. Furthermore it was demonstrated that undesired transfec-
tion of lung and liver was significantly reduced, compared to L-PEI. Using lt-OEI-
HD1.2 formulations in a w/w ratio of 1.4 tumor transfection reached the same level as 
with L-PEI. If transferrin-containing complexes were applied, increasing w/w ratio and 
increasing transfection efficiency tended to be corrrelated, however, differences were 
no longer significant. In summary, we have found that the biodegradable polymers 
OEI-HD and lt-OEI-HD1.2 can reach similar transfection efficiencies as L-PEI in vivo, 
while showing an improved toxicity profile. Long-term treatment with L-PEI is re-
stricted due to its non-biodegradability and accumulation in the body. In contrast, 
OEI-HD and lt-OEI-HD1.2 are degradable under physiological conditions (Kloeckner 
et al. 2006-3) and therefore enable long-term therapy with repeated applications. 
4 Discussion 76 
 
4.2.2 Influence of CpG motifs in pDNA on transfection efficiency 
The primary signal for the mammalian innate immune system to recognize incoming 
foreign DNA is triggered by unmethylated CpG motifs present in the DNA sequences 
of various disease-causing pathogens. These motifs are rare in mammalians, but 
abundant in bacterial DNAs. As gene therapy typically involves delivery of bacterial 
derived DNA, an acute inflammatory response and silencing effects may influence 
results. Furthermore, bacterial genomic DNA containing nonmethylated CpG se-
quences represents a typical impurity of plasmid preparations which might also trig-
ger inflammatory responses (Li et al. 1999, Krieg et al. 1995, Yew et al. 2000, Krieg 
2003, Klinman 2004, Chevalier-Mariette et al. 2003).  
For use of pDNA in pharmaceutical products, the FDA has set the following require-
ments for final specifications: 
 Analytical method Specification 
Endotoxins LAL assay < 40 E.U./mg pDNA 
Genomic DNA RT-PCR preferably < 1 % /mg pDNA 
RNA Agarose-gelelectrophoresis preferably < 1 % /mg pDNA 
Proteins BCA assay preferably < 1 % /mg pDNA 
pDNA/cccDNA Agarose-gelelectrophoresis > 80 % 
Table 4-I: FDA requirements for pDNA used in pharmaceutical products (source: FDA con-
siderations for plasmid DNA vaccines for infectious disease indications: 
http://www.fda.gov/cber/gdlns/plasdnavac.htm) 
In our studies two different plasmids which differed in their CpG motif content were 
used. Both plasmids were purified using different methods resulting in impurity levels 
of ~ 10 % genomic DNA (research grade (RG)) and ~ 1 % genomic DNA (covalently 
closed circular plasmid grade (ccc)).  
The study included two different ways of administration: (a) standard intraveneous 
injection of pDNA / L-PEI polyplexes and (b) hydrodynamic application with free 
plasmids. 
 
4 Discussion 77 
 
L-PEI is widely used in in vivo gene delivery and known for its versatility and com-
paratively high transfection efficiency in the lung and therefore was chosen as a 
standard in this study (Dif et al. 2006). Moreover, since the beginning of 2008 L-PEI 
is available in GMP-quality by Polyplus-transfection (jetPEITM) and used as delivery 
reagent in clinical trials for cancer therapy in Israel and the USA (Ohana et al. 2004) 
and for HIV immune therapy in Germany and Sweden (Lisziewicz et al. 2005-1, 
Lisziewicz et al. 2005-2). Furthermore, it was shown that injection of L-PEI alone did 
not induce any pro-inflammatory response (Bonnet et al. 2008). Effects on the innate 
immune system could therefore be linked to pDNA itself.  
Systemic administration of polyplexes indicated that transfection efficiency with 
pCpGLuc polyplexes lead to increased results compared to pEGFPLuc polyplexes. 
However, the differences between the two purification grades of one plasmid dis-
played only minor variations in transgene expression. In a second step it was shown 
that the N/P ratio chosen for complex formation plays a critical role in transfection 
efficacy. By forming complexes at a N/P ratio of 9 instead of 6, a significant difference 
between transgene expression of purified and research grade pCpGLuc polyplexes 
was detected.  
For hydrodynamic delivery of the free plasmids a dose of 1.25 mg plasmid / kg was 
applied (Hibbitt et al. 2007, Woodell et al. 2008) . No difference was detected be-
tween the purification grades of the plasmids. Interestingly, gene expression after 
application of pEGFPLuc plasmid rapidly decreased, while application of pCpGLuc 
plasmid resulted in an almost constant gene expression over a time-period of about 
two weeks. Gene expression of the two plasmids (pCpGLuc and pEGFPLuc) de-
creased to similar levels after 3 weeks. It was reported that CpG motifs can provoke 
gene silencing (Chevalier-Mariette et al. 2003, Bird 2002). Since both pEGFPLuc 
plasmid grades contain CpG sequences gene silencing is a potential explanation for 
the observed difference. A second aspect which might be taken into consideration are 
genomic DNA impurities since these contain CpG motifs as well. The difference in 
impurity levels between RG and ccc plasmids might therefore result in different levels 
of gene silencing. However, no significant difference was found between the different 
purification grades. Other points to consider are the different promoters of the two 
plasmids, as it has been recently shown that plasmids containing the EGF1 promotor 
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(as the pCpGLuc plasmid) show an increased liver transfection efficiency compared 
to plasmids with the hCMV promoter (pEGFPLuc) (Nguyen et al. 2008).  
A potential reason for the differing results in duration of gene expression obtained 
with classical systemic and hydrodynamic intravenous application, might be due to 
the different circulation time of plasmid in the body. Intravenous injection of poly-
plexes results in short circulation of the particles in the blood. During this short period 
particles get in contact with a high surface area and might lead to cytokine expres-
sion (Merdan et al. 2005, Kawakami et al. 2006), followed by gene silencing. In con-
trast, hydrodynamic tail vein application of plasmid leads to rapid uptake into liver 
cells. Due to the high volume injected, an increased pressure in the vena cava is 
created, pushing the plasmid solution in the large hepatic vein and from there out of 
the capillaries directly into the liver tissue. This procedure leads to an immediate up-
take of about 90 % of injected plasmid in the liver (Herweijer and Wolff 2007). Cyto-
kine induction in the blood therefore is minimized. 
 5 Summary 
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For the development of potent nucleic acid (NA) delivery systems different items 
have to be optimised. Depending on the treatment strategy it might be useful to work 
with plasmid DNA or siRNA as a vector. For effective transport to the desired cells of 
action, targeted vectors have to be developed that ideally are non toxic, can be ex-
creted from the body, protect the NA in blood flow and transport them securely and 
predominantly to the favoured cells. This thesis describes in vivo studies on the influ-
ence of delivery systems on pDNA and siRNA delivery as well as the influence of 
pDNA structure on efficient gene transfer. A second goal was to clarify potential toxic 
effects of delivery systems as well as of NAs following systemic application.  
Part 1 describes the effective delivery of a therapeutic RAN siRNA to subcutaneous 
tumors in mice. The polymer OEI-HD, based on beta-propionamide-cross-linked oli-
goethylenimine and its chemical transferrin conjugate were evaluated for siRNA de-
livery into murine Neuro2A neuroblastoma cells in vivo. The Ras-related nuclear pro-
tein RAN was selected as a therapeutically relevant target protein. Systemic delivery 
of transferrin-conjugated OEI-HD/RAN siRNA formulations (three intravenous appli-
cations at 3 days interval) resulted in apoptosis, >80% reduced Ran protein expres-
sion, 40 % Ran mRNA expression and a reduced tumor growth in Neuro2A tumors of 
treated mice. The treatment was not associated with signs of acute toxicity or signifi-
cant changes in weight, hematology parameters, or liver enzymes (AST, ALT, or AP) 
of mice. All our results demonstrate that OEI-HD/siRNA formulations are well toler-
ated and can knockdown genes in tumor cells in vivo in mice without unspecific toxic-
ity. 
In part 2 a novel polymer for siRNA delivery was investigated. Initial in vivo experi-
ments with the therapeutic Ran siRNA led to a significantly reduced tumor growth. 
However, in a following detailed investigation it could be shown that this effect was 
not due to the siRNA but to the polymer itself. As the analyzed polymer is hydropho-
bically modified, it easily interacts with cell membranes, as for example tumor vessels 
thereby leading to necrosis. In a next step poloxamer containing formulations with 
reduced toxicity were tested, but were ineffective. Further investigations on this field 
are inevitable.  
In part 3 the comparison of different gene delivery vectors for pDNA delivery in vivo 
was accomplished. Three different cationic polymers were analyzed concurrently with 
regards to their ability to degrade within the in vivo circulation. It was hypothesized 
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that cationic vectors can be developed to show in vivo transfection efficiency that is 
comparable with that of the gold standard L-PEI, however, due to their biodegradable 
structure, these vectors should confess the ability to be excreted, thus would be well 
tolerated after repeated application. When complexed together with pDNA and trans-
ferrin-conjugates to target Neuro2A tumor cells, efficient transfection of tumor tissue 
was obtained with all polymers, showing no significant difference between efficiency 
of L-PEI and the two degradable polyplexes. Biophysical characterizations regarding 
DNA complexation and complexation ability, size and surface charge were investi-
gated and did not show differences between L-PEI and the degradable polymers ei-
ther. However, the polymers with potential to degrade indeed showed better results in 
vivo regarding acute toxicity.  
Part 4 deals with the question how pDNA should ideally be designed to give long 
lasting gene expression. Analyzed were (i) the influence of CpG sequences within the 
plasmid and (ii) the influence of remaining genomic DNA. Furthermore it was exam-
ined whether these influences varied after changing routes of in vivo application. To 
clear this question, in one setting pDNAs were applied to BALB/c mice by hydrody-
namic tail vein injection and in the other setting plasmid DNAs were complexed to L-
PEI to lead to efficient lung transfection after low pressure tail vein injection. Meas-
urement of transgene expression by in vivo imaging revealed a strong influence of 
CpG motifs regardless of the way of administration. Nevertheless only with low pres-
sure polyplex application, a positive influence on transfection efficiency of the purifi-
cation from genomic DNA from 10 down to 1 % was significant. In the hydrodynamic 
application setting a reduction of genomic DNA content down to 1 % did not result in 
significant differences. These results highlight the influence of the plasmid for the effi-
ciency of long-term gene expression for systemic application of free and complexed 
pDNA. The influence of up to 10 % genomic DNA in a plasmid solution however 
seems to be dependent on the method of application. 
 
 6 Appendices 
6 Appendices 83 
 
6.1 Abbreviations 
BBB blood brain barrier 
ccc covalently closed circular (supercoiled) 
DAPI 4’,6-diamidino-2-phenylindole, dihydrochloride 
DOPC dioleoylphosphatidylcholine 
DOPE dioleoylphosphatidylethanolamine 
DPPC dipalmitoylphosphatidylcholine 
pDNA plasmid DNA 
EtBr ethidium bromide 
FDA US food and drug administration 
GMP good manufacturing practice  
HBG HEPES buffered glucose 
HBS HEPES buffered saline 
HE hematoxylin-eosin 
HEPES 2-[4-(2-Hydroxyethyl)-1-piperazinyl]ethanesulfonic acid 
LAL Limulus Amebocyte Lysate 
L-PEI linear polyethyleneimine 
OEI oligoethylenimine 
MW mean value 
Mw molecular weight 
N/P  nitrogen / phosphate  
NA nucleic acid 
PBS phosphate buffered saline 
PEG polyethylene glycol 
RG research grade 
RLU relative light units 
mRNA messenger RNA 
siRNA short interfering RNA 
SD standard deviation 
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TUNEL TdT-mediated dUTP-biotin nick end labeling 
VDA vascular disrupting agent 
w weight 
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